[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112428
1. Cantarero Vallejo MD, Gómez Camarero J, Menchén L, Pajares Díaz JA, Lo Iacono O: [Liver damage and celiac disease]. Rev Esp Enferm Dig; 2007 Nov;99(11):648-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver damage and celiac disease].
  • In fact, a wide spectrum of liver injuries in children and adults may be related to CD, particularly: a) mild parenchymal damage characterized by absence of any clinical signs or symptoms suggesting chronic liver disease, and by non-specific histological changes reversible on a gluten-free diet;.
  • b) chronic liver damage with autoimmune etiology, including autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis, which may be associated with CD but are generally unaffected by gluten withdrawal; and c) severe liver failure and decompensated cryptogenetic liver cirrhosis, potentially treatable with a gluten-free diet.
  • Such different types of liver injuries may represent one same disorder where individual factors, such as genetic predisposition, precocity, and duration of exposure to gluten may influence reversibility of liver damage.
  • A rigorous cross-checking for asymptomatic liver damage in CD individuals and, conversely, for CD in any cryptogenic liver disorder, including end-stage liver failure, is recommended.
  • [MeSH-major] Celiac Disease / complications. Liver Diseases / complications

  • Genetic Alliance. consumer health - Celiac Disease.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271663.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 52
  •  go-up   go-down


2. Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD: Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci; 2009 Jul;110(1):47-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice.
  • Farnesoid X receptor (FXR) and pregnane X receptor (PXR) are two major bile acid sensors in liver.
  • The purpose of this study was to characterize the regulation of hepatic transporters by FXR and PXR during ANIT-induced liver injury.
  • Livers from wild-type and PXR-null mice had comparable multifocal necrosis 48 h after ANIT.
  • However, ANIT-treated FXR-null mice have fewer and smaller necrotic foci than wild-type mice but had scattered single-cell hepatocyte necrosis throughout the liver.
  • Serum and liver unconjugated bile acids were higher in ANIT-treated FXR-null mice than the other two genotypes.
  • ANIT induced mRNA expression of Mdr2, Bsep, and Atp8b1 in wild-type and PXR-null mice but failed to upregulate these genes in FXR-null mice. mRNA expression of uptake transporters declined in livers of all genotypes following ANIT treatment.
  • ANIT increased Ostbeta and Mrp3 mRNA in livers of wild-type and PXR-null mice but did not alter Ostbeta mRNA in FXR-null mice.
  • In conclusion, FXR deficiency enhances susceptibility of mice to ANIT-induced liver injury, likely a result of impaired induction of hepatobiliary efflux transporters and subsequent hepatic accumulation of unconjugated bile acids.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 2000 Aug;14(4):571-83 [10976015.001]
  • [Cites] Dig Liver Dis. 2000 Mar;32(2):152-9 [10975791.001]
  • [Cites] Mol Pharmacol. 2001 Mar;59(3):627-35 [11179459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74 [11248085.001]
  • [Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]
  • [Cites] Hepatology. 2002 Mar;35(3):589-96 [11870371.001]
  • [Cites] Endocr Rev. 2002 Aug;23(4):443-63 [12202460.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1236-45 [12395335.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):633-71 [12663868.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):1037-42 [12671900.001]
  • [Cites] J Hepatol. 2003 Jun;38(6):717-27 [12763363.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):480-8 [12971955.001]
  • [Cites] Annu Rev Biochem. 2003;72:137-74 [12543708.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1678-87 [14623915.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):756-64 [14988830.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):539-51 [15123373.001]
  • [Cites] Hum Mol Genet. 2004 Oct 15;13(20):2451-60 [15317749.001]
  • [Cites] Am J Med. 1971 Nov;51(5):568-79 [4399226.001]
  • [Cites] Gastroenterology. 1976 Aug;71(2):202-7 [939378.001]
  • [Cites] Pharmacol Rev. 1976 Sep;28(3):207-73 [16281.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Jan;256(1):412-20 [1846424.001]
  • [Cites] Biochem Pharmacol. 1991 Nov 6;42(11):2171-80 [1958235.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):235-40 [7989715.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1469-74 [7503798.001]
  • [Cites] Hepatology. 1997 Jun;25(6):1539-42 [9185779.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):966-72 [9287990.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):10046-50 [9545351.001]
  • [Cites] Toxicol Sci. 2005 Jan;83(1):44-52 [15496496.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):759-66 [15466244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2063-8 [15684063.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):1062-73 [15843488.001]
  • [Cites] Drug Metab Dispos. 2005 Sep;33(9):1276-82 [15919853.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G798-805 [16002565.001]
  • [Cites] Hepatology. 2005 Dec;42(6):1270-9 [16317684.001]
  • [Cites] Hepatology. 2006 May;43(5):1013-21 [16628672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11323-8 [16844773.001]
  • [Cites] Drug Metab Dispos. 2006 Nov;34(11):1863-7 [16928788.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1768(3):637-47 [17141734.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):96-105 [17592371.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):507-16 [17681172.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 1;873(2):209-17 [18801708.001]
  • [Cites] Acta Gastroenterol Belg. 1999 Jul-Sep;62(3):300-5 [10547896.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2905-10 [10644759.001]
  • [Cites] Drug Metab Dispos. 2000 May;28(5):608-16 [10772642.001]
  • [Cites] Cell. 2000 Sep 15;102(6):731-44 [11030617.001]
  • (PMID = 19407337.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES009716; United States / NIEHS NIH HHS / ES / R01 ES013714; United States / NIEHS NIH HHS / ES / T32 ES007079; United States / NIEHS NIH HHS / ES / ES-009716; United States / NIEHS NIH HHS / ES / ES-009649; United States / NIEHS NIH HHS / ES / R01 ES009649; United States / NIEHS NIH HHS / ES / ES-007079; United States / NIEHS NIH HHS / ES / ES-013714
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers; 0 / Carrier Proteins; 0 / GW 4064; 0 / Isoxazoles; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / farnesoid X-activated receptor; 0 / pregnane X receptor; 551-06-4 / 1-Naphthylisothiocyanate; 63231-63-0 / RNA; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2696329
  •  go-up   go-down


3. Halazun KJ, Al-Mukhtar A, Aldouri A, Malik HZ, Attia MS, Prasad KR, Toogood GJ, Lodge JP: Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role. Ann Surg; 2007 Dec;246(6):1065-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role.
  • OBJECTIVE: To assess the results of 275 patients undergoing right hepatic trisectionectomy and to clarify its current role.
  • SUMMARY BACKGROUND DATA: Right hepatic trisectionectomy is considered one of the most extensive liver resections, and few reports have described the long-term results of the procedure.
  • METHODS: Short- and long-term outcomes of 275 consecutive patients who underwent right hepatic trisectionectomy from January 1993 to January 2006 were analyzed.
  • RESULTS: Of the 275 patients, 160 had colorectal metastases, 49 had biliary tract cancers, 20 had hepatocellular carcinomas, 20 had other metastatic tumors, and 12 had benign diseases.
  • Fourteen of the 275 patients underwent right hepatic trisectionectomy as part of auxiliary liver transplantation for acute liver failure and were excluded.
  • Concomitant procedures were carried out in 192 patients: caudate lobectomy in 45 patients, resection of tumors from the liver remnant in 57 patients, resection of the extrahepatic biliary tree in 45 patients, and lymphadenectomy in 45 patients.
  • Survivals for individual tumor types were acceptable, with 5-year survivals for colorectal metastasis and cholangiocarcinoma being 38% and 32%, respectively.
  • CONCLUSION: Right hepatic trisectionectomy remains a challenging procedure.
  • The outcome is not influenced by additional concomitant resection of tumors from the planned liver remnant.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jul;248(1):138-9; author reply 139-40 [18580219.001]
  • (PMID = 18043112.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After confirmation of normal liver function, 5-ALA was administered orally (20 mg/kg) within 3-5 h prior to skin incision.
  • Intraoperative 440 nm fluorescence was applied periodically during and at the end of resection in order to detect tumor-infiltrated sites.
  • The fluorescence of the tumor was evaluated intraoperatively by the surgeon and confirmed by subsequent video analysis.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • 5-ALA-induced fluorescence of the tumor was confirmed in a total of 31 (94%) patients.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care / methods. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


5. Increased liver regeneration rate and decreased liver function after synchronous liver and colon resection in rats. Ann Surg Innov Res; 2009 Dec 24;3:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased liver regeneration rate and decreased liver function after synchronous liver and colon resection in rats.
  • BACKGROUND: The surgical strategy for the treatment of colorectal cancer and synchronous liver metastases remains controversial.
  • The aim of the present study was to investigate the effects of colonic resection on liver function and regeneration in a rat model.
  • Group III and V had 40% or 70% of the liver resected, respectively.
  • Remnant liver function was evaluated by means of branched amino acids to tyrosine ratio.
  • Liver regeneration was calculated by (liver weight per 100 g of the body weight at sacrifice/preoperative projected liver weight per 100 g of the body weight) x 100.
  • Body weight and branched amino acids to tyrosine ratio were both significantly lower in rats that had simultaneous colonic and liver resection performed.
  • Hepatic regeneration rate was significantly higher in the simultaneous colectomy group.
  • CONCLUSIONS: In our model morbidity seems to be related to the extent of hepatic resection.
  • In rats undergoing liver resection, simultaneous colectomy induced a higher degree of hepatic regeneration rate.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem Biophys Methods. 1989 Mar;18(2):97-104 [2663963.001]
  • [Cites] Dev Immunol. 2002 Sep;9(3):143-9 [12885155.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):54-60 [11120636.001]
  • [Cites] Am J Physiol. 1985 Nov;249(5 Pt 2):R551-62 [2865902.001]
  • [Cites] Eur Surg Res. 1995;27(6):396-405 [8542925.001]
  • [Cites] Scand J Gastroenterol. 1976;11(8):857-63 [794999.001]
  • [Cites] Hepatology. 1981 Sep-Oct;1(5):424-30 [7030905.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] J Reticuloendothel Soc. 1982 Dec;32(6):409-22 [7161770.001]
  • [Cites] Surgery. 1987 Nov;102(5):846-51 [2823408.001]
  • [Cites] J Clin Lab Anal. 1999;13(1):31-4 [10025735.001]
  • [Cites] Eur J Clin Invest. 2008 Sep;38(9):640-8 [18837740.001]
  • [Cites] Surg Today. 1999;29(8):825-7 [10483769.001]
  • [Cites] Am Surg. 1992 Feb;58(2):88-91 [1550311.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1405-16 [10573519.001]
  • [Cites] Hepatogastroenterology. 2008 Mar-Apr;55(82-83):641-6 [18613424.001]
  • [Cites] Gastroenterology. 1977 Jun;72(6):1268-70 [858472.001]
  • [Cites] Eur Surg Res. 2007;39(1):17-22 [17164549.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):148-52 [3947153.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • (PMID = 20034379.001).
  • [ISSN] 1750-1164
  • [Journal-full-title] Annals of surgical innovation and research
  • [ISO-abbreviation] Ann Surg Innov Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806264
  •  go-up   go-down


6. Gruttadauria S, Vizzini G, Biondo D, Mandalà L, Volpes R, Palazzo U, Gridelli B: Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience. Liver Transpl; 2008 Feb;14(2):220-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience.
  • This study presents our experience with the use of extended criteria donor (ECD) liver grafts.
  • One hundred fifteen liver transplants were divided into 2 groups: standard (S) and nonstandard (NS).
  • Fifty-eight patients in group S received a liver procured from an ideal donor, whereas 57 patients in group NS received an organ from an ECD.
  • In the multivariate analysis, which was adjusted for recipient age and donor and recipient gender, hemodynamic risk factors and Model for End-Stage Liver.
  • Critical use of ECD liver grafts allowed recipients in the waiting list to have a greater chance of being transplanted.
  • [MeSH-major] Graft Rejection / etiology. Graft Survival. Liver Diseases / surgery. Liver Transplantation / methods. Living Donors. Patient Selection


7. Gangi A, Basile A, Buy X, Alizadeh H, Sauer B, Bierry G: Radiofrequency and laser ablation of spinal lesions. Semin Ultrasound CT MR; 2005 Apr;26(2):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor ablation guided with medical imaging proved a high local efficacy over 90% for tumors less than 25 mm in the liver, lung, and kidney.
  • First, the tumor ablation is reviewed with malignant and benign tumors.
  • In malignant tumors, radiofrequency is very efficient in local tumor control and in pain management.
  • [MeSH-major] Catheter Ablation / methods. Electrosurgery / methods. Intervertebral Disc / surgery. Laser Therapy / methods. Osteoma, Osteoid / surgery. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Semin Ultrasound CT MR. 2005 Oct;26(5):304. Basille, A [corrected to Basile, A]
  • (PMID = 15856810.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


8. Vascotto C, Cesaratto L, D'Ambrosio C, Scaloni A, Avellini C, Paron I, Baccarani U, Adani GL, Tiribelli C, Quadrifoglio F, Tell G: Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics; 2006 Jun;6(11):3455-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation.
  • Knowledge of early molecular events occurring upon ischemia/reperfusion (I/R) during liver transplantation (LT) is of great importance to improve the therapeutic intervention of surgical treatment.
  • To identify these proteins, we used a differential proteomics approach in the characterization human liver biopsies during I/R upon LT.
  • Analyses were performed on nine donor livers during LT.
  • By using 2-DE and MALDI-TOF MS, we identified 36 proteins which resulted significantly altered upon I/R injury.
  • Our data represent the first global approach in the study of I/R injury in liver.
  • [MeSH-major] Liver / chemistry. Liver Transplantation. Proteome / analysis. Reperfusion Injury / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622838.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


9. Karlberg N, Karlberg S, Karikoski R, Mikkola S, Lipsanen-Nyman M, Jalanko H: High frequency of tumours in Mulibrey nanism. J Pathol; 2009 Jun;218(2):163-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of tumours in Mulibrey nanism.
  • Mulibrey nanism (MUL) is a monogenic disorder with prenatal-onset growth failure, typical clinical characteristics, cardiopathy and tendency for a metabolic syndrome.
  • In this work, the frequency and pathology of malignant and benign tumours were analysed in a national cohort of 89 Finnish MUL patients aged 0.7-76 years.
  • The results show that the MUL patients have disturbed architecture with ectopic tissues and a high frequency of both benign and malignant tumours detectable in several internal organs.
  • Fifteen malignancies occurred in 13 patients (15%), seven of them in the kidney (five Wilms' tumours), three in the thyroid gland, two gynaecological cancers, one gastrointestinal carcinoid tumour, one neuropituitary Langerhans cell histiocytosis and one case of acute lymphoblastic leukaemia (ALL).
  • Tumours detected by radiology in the liver and other organs mainly comprised strongly dilated blood vessels (peliosis), vascularized cysts and nodular lesions.
  • Our findings show that MUL is associated with frequent malignant tumours and benign adenomatous and vascular lesions, as well as disturbed organ development.
  • [MeSH-major] Mulibrey Nanism / complications. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / pathology. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Finland. Heart Neoplasms / complications. Heart Neoplasms / pathology. Humans. Infant. Kidney Neoplasms / complications. Kidney Neoplasms / pathology. Liver Neoplasms / complications. Liver Neoplasms / pathology. Lung Neoplasms / complications. Lung Neoplasms / pathology. Male. Middle Aged. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / pathology. Prevalence. Thyroid Neoplasms / complications. Thyroid Neoplasms / pathology. Wilms Tumor / complications. Wilms Tumor / pathology


10. Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL: Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer. J Cancer Res Clin Oncol; 2010 Sep;136(9):1349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
  • RESULTS: We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011).
  • Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002).
  • Increasing the risk of tumor metastasis (OR = 3.889).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / enzymology. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Invasiveness / diagnosis. Prognosis. RNA, Messenger / biosynthesis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 2008 Aug;22(2):187-92 [18636172.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2922-6 [17409395.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):151-9 [17592549.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1307-12 [18684031.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):303-10 [17235563.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2195-204 [15788667.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1179-84 [17440740.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Surg Today. 2007;37(8):646-51 [17643206.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1439-47 [18561324.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Science. 2001 Oct 12;294(5541):281-2 [11598274.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11882-9 [14704153.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9625-35 [17018620.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):303-14 [18471976.001]
  • (PMID = 20140626.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


11. Laca L, Urdzik J, Dobrota FM, Polácek H: [Limitations of liver resections]. Rozhl Chir; 2009 Mar;88(3):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limitations of liver resections].
  • Evaluation of the functional reserve before resectional performance and sufficient rest of liver parenchyma function is essential for the surgeon.
  • From these factors, the decision based on operability, the maximum extent of liver parenchyma resection and the severity of post-operative course.
  • In the period from December 2003 to December 2008, at the Dept of Transplant and Vascular surgery, JLF UK Martin, have been performed 161 resections of the liver in 144 patients, of which 91 large resections performances in the liver (hemihepatektomies or greater performance).
  • Of 91 major resection performance in the liver was 62 (68%) performed by anatomical boundaries of individual segments, in remaining 29 (32%) resections was reflected more to the localization of tumor itself as anatomical subdivision called combined anatomical and non-antomical resection.
  • Radical resection R0 has been achieved in 76% of malignant tumors.
  • In the post-operative course in 17% experienced complications, most often to the hematoma and biloma in place of the resection area, pleural effusion and 8 patients had postoperative liver dysfunction.
  • Of this group, 5 patients had made volumetric examinations, and in all was the volume of residual liver parenchyma < 30% of the total volume of functional liver.
  • The survival of patients was affected mainly by extent of resection, histological type of tumor, radicality of resection and necessity of the complex surgical procedures.
  • Based on our evaluation of the results of a group of patients was arranged scheme measures for planning resectional procedures of the liver in our department.
  • These include the adjustment of laboratory parameters, management of jaundice, preference of anatomical resections and volumetric examinations in patients with an estimated loss of more than 60-70% functional parenchyma of liver.
  • [MeSH-minor] Female. Humans. Liver / physiopathology. Male. Middle Aged. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526944.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V: Biomarkers of liver fibrosis. Adv Clin Chem; 2008;46:131-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers of liver fibrosis.
  • Liver biopsy, due to its limitations and risks, is an imperfect gold standard for assessing the severity of the most frequent chronic liver diseases.
  • This chapter summarized the advantages and the limits of the available biomarkers of liver fibrosis.
  • The mean diagnostic value for the diagnosis of advanced fibrosis assessed using standardized area under the receiver operating characteristics (ROC) curves was 0.84 [95% confidence interval (CI), 0.83-0.86], without significant difference between the causes of liver disease, hepatitis C, hepatitis B, alcoholic or nonalcoholic fatty liver disease.
  • Due to the evidence-based data, health authorities in some countries have already approved validated biomarkers as first-line procedure for the staging of liver fibrosis.
  • This overview of evidence-based data suggests that biomarkers could be used as an alternative to liver biopsy for the assessment of fibrosis stage in the four more common chronic liver diseases: C virus (HCV), hepatitis B virus (HBV), hepatitis nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD).
  • [MeSH-major] Liver Cirrhosis / diagnosis
  • [MeSH-minor] Biomarkers. Biopsy. Humans. Liver / pathology. Patents as Topic

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004189.001).
  • [ISSN] 0065-2423
  • [Journal-full-title] Advances in clinical chemistry
  • [ISO-abbreviation] Adv Clin Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 109
  •  go-up   go-down


13. Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N: Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol; 2009 Apr;24(4):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation.
  • AIM: We evaluated the expression of hepatitis C virus (HCV) antigen on liver grafts by immunohistochemical staining (IHS) using IG222 monoclonal antibody (mAb) against HCV-envelope 2 (E2).
  • METHODS: The study material was 84 liver biopsy specimens obtained from 28 patients who underwent living donor liver transplantation (LDLT) for HCV infection.
  • There was no significant correlation between the IHS grades using IG222 mAb and serum HCV-RNA levels when data of 84 liver biopsy specimens were analyzed.
  • CONCLUSIONS: Constant HCV-E2 expression was observed in liver biopsy specimens obtained 1 month or longer.
  • The strong HCV-E2 expression on liver grafts were associated with recurrent hepatitis C after LDLT, but the serum HCV-RNA levels were not.
  • [MeSH-major] Hepacivirus / isolation & purification. Hepatitis C / virology. Immunohistochemistry. Liver / virology. Liver Cirrhosis / surgery. Liver Transplantation. Living Donors. Viral Envelope Proteins / analysis


14. Wang WL, Zheng SS, Xu X, Liang TB, Jin J, Shen Y, Zhang M, Wu J: [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3460-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases].
  • OBJECTIVE: To evaluate the efficacy of emergency liver transplantation in treating patients with benign end-stage liver diseases and explore the possible prognostic factors.
  • CONCLUSION: Emergency liver transplantation is an effective treatment to salvage patients in end-stage.
  • [MeSH-major] Hepatitis B / surgery. Liver Cirrhosis / surgery. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686060.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


16. Deaciuc IV, Song Z, Peng X, Barve SS, Song M, He Q, Knudsen TB, Singh AV, McClain CJ: Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease. Hepatol Int; 2008 Mar;2(1):39-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease.
  • PURPOSE: To perform a large-scale gene profiling of the liver in a mouse model of fatty liver induced by high carbohydrate (sucrose) diet (HCD) to gain a deeper insight into potential mechanisms of diet-induced hepatic steatosis.
  • HCD feeding led to marked liver steatosis without inflammation or necrosis.
  • The genes that underwent expression changes perform a large variety of molecular functions, and the vast majority of these have never been tested before in non-alcoholic fatty liver of nutritional origin.
  • They reveal novel aspects of the disease and allow identification of candidate genes that may underlie the initiation of hepatic steatosis and progression to non-alcoholic steatohepatitis.
  • CONCLUSIONS: HCD-fed laboratory animals provide a model of early non-alcoholic fatty liver disease resembling the disease in humans.
  • The genome wide gene profiling of the liver reveals the complexity of the disease, unravels novel aspects of HCD-induced hepatic steatosis, and helps elucidate its nature and mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr Biochem. 2007 Mar;18(3):184-95 [17296492.001]
  • [Cites] Am J Clin Nutr. 1980 May;33(5):1108-39 [6989228.001]
  • [Cites] Ann Intern Med. 2005 Nov 15;143(10):722-8 [16287793.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1663-74 [16285964.001]
  • [Cites] Hepatology. 2005 Oct;42(4):905-14 [16175602.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20010-20 [15753094.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):99-105 [15860251.001]
  • [Cites] CMAJ. 2005 Mar 29;172(7):899-905 [15795412.001]
  • [Cites] Clin Biochem. 2005 Mar;38(3):203-17 [15708540.001]
  • [Cites] Alcohol. 2004 Aug;34(1):67-79 [15670668.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Biochimie. 2004 Nov;86(11):839-48 [15589694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1964 Nov;52:1255-63 [14231450.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3640-8 [13990010.001]
  • [Cites] Hepatology. 1999 May;29(5):1602-4 [10216149.001]
  • [Cites] Adv Enzyme Regul. 1996;36:199-226 [8869748.001]
  • [Cites] Ann N Y Acad Sci. 1982;393:32-47 [6959560.001]
  • [Cites] Clin Liver Dis. 2004 Aug;8(3):559-74, ix [15331064.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36650-9 [15194686.001]
  • [Cites] J Clin Invest. 2004 Jul;114(2):147-52 [15254578.001]
  • [Cites] Alcohol. 2004 Feb;32(2):113-27 [15163562.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):502-9 [14985228.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):219-27 [14739091.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):978-83 [14642615.001]
  • [Cites] J Lipid Res. 2003 Apr;44(4):846-53 [12562844.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):43-50 [12499321.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;967:19-27 [12079831.001]
  • [Cites] Hepatology. 2001 May;33(5):1239-58 [11343254.001]
  • [Cites] J Soc Biol. 2001;195(3):243-8 [11833461.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Gene Expr. 2000;9(1-2):63-75 [11097425.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):1-6 [11121095.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2081-91 [8621798.001]
  • [Cites] Environ Res. 1992 Oct;59(1):238-49 [1425514.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):835-8 [16356442.001]
  • (PMID = 19669278.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716868
  •  go-up   go-down


17. Rakela B J: [Liver disease recurrence after liver transplantation]. Rev Med Chil; 2010 Apr;138(4):504-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver disease recurrence after liver transplantation].
  • [Transliterated title] Recurrencia de la enfermedad hepática primaria después del trasplante hepático.
  • Liver transplantation has become a standard option in the management of patients with end-stage liver disease.
  • It is now evident that the most common etiology of long-term graft dysfunction is the recurrence of the primary liver disease.
  • Autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis recur between 15 to 30% of the graft recipients.
  • The clinical expression of this recurrence tends to be milder; the diagnosis is only established in many patients by findings in the liver biopsy.
  • The recurrence of hepatitis C virus infection is characterized by an accelerated progression towards cirrhosis and hepatic failure due to the lack of an effective immunoprophylaxis program and an effective antiviral therapy.
  • The liver from these patients, apart from producing this abnormal protein, is otherwise normal, and has been used as an organ for recipients in dire need of a liver transplant, such as patients with hepatocellular carcinoma.
  • This approach is known as domino liver transplantation.
  • As these recipients are followed long term, they may develop de novo amyloidosis.
  • In summary, the underlying liver condition that led to endstage liver disease and liver transplantation may recur after liver transplantation.
  • The clinical expression of the recurrence of the hepatic disease is modulated by the immunosuppression program unless we have an effective immunoprophylaxis and antiviral agents such as in hepatitis B.
  • [MeSH-major] Cholangitis, Sclerosing. Hepatitis, Autoimmune. Liver Cirrhosis, Biliary / prevention & control. Liver Transplantation. Postoperative Complications


18. Nedzi LA: The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol; 2008 Oct;18(4):265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retrospective published experience in functional and benign tumor radiosurgery is reviewed.
  • Prospective controlled clinical trials in ablative cancer therapy of early-stage lung cancer and metastatic disease in the brain, liver, and spine are reviewed.
  • [MeSH-minor] Brain / radiation effects. Humans. Neoplasms / radiotherapy. Nervous System Diseases / radiotherapy. Radiation Injuries / prevention & control. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725114.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


19. Malik R, Saich R, Rahman T, Hodgson H: During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease. Dig Dis Sci; 2006 Dec;51(12):2235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease.
  • In toxic liver injury, proliferation of preexisting hepatocytes helps restore liver mass and function.
  • While loss of liver mass per se stimulates hepatocyte proliferation, exogenous mitogens have a potential role in enhancing liver regeneration.
  • The aim of this study was to characterize the effects of the mitogen, tri-iodothyonine, on the regenerative capacity of hepatocytes during thioacetamide-induced liver failure.
  • Liver cell proliferation was assessed and comparison made with other control groups receiving tri-iodothyonine or vehicle only.
  • We conclude that the ability of hepatocytes in the midzonal areas of rat liver to proliferate in response to tri-iodothyonine is maintained during severe acute toxic injury.
  • [MeSH-major] Cell Proliferation / drug effects. Hepatocytes / drug effects. Liver Failure, Acute / pathology. Triiodothyronine / pharmacology
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Liver Regeneration / drug effects. Male. Mitogens / pharmacology. Random Allocation. Rats. Thioacetamide

  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1990 May;10(3):332-6 [2195108.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):535-52 [1716045.001]
  • [Cites] Am J Surg. 2002 Apr;183(4):457-63 [11975936.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1994 Aug;85(2):157-62 [7994560.001]
  • [Cites] Liver. 1999 Dec;19(6):519-25 [10661686.001]
  • [Cites] Semin Liver Dis. 2003 Aug;23(3):203-15 [14523674.001]
  • [Cites] Physiol Rev. 1986 Jul;66(3):499-541 [2426724.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):385-96 [11469916.001]
  • [Cites] Hepatology. 1994 Nov;20(5):1237-41 [7927257.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1099-109 [1683163.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):857-63 [9047393.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):425-31 [12468243.001]
  • [Cites] Hepatology. 2003 Jan;37(1):79-86 [12500192.001]
  • [Cites] Dig Dis Sci. 2002 Oct;47(10):2170-8 [12395888.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] Life Sci. 2003 Jan 3;72 (7):851-61 [12479984.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1013-20 [9537441.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1118-28 [8751714.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):815-24 [8774136.001]
  • [Cites] J Hepatol. 2003 May;38(5):583-90 [12713868.001]
  • [Cites] Arch Surg. 2001 Dec;136(12):1377-80 [11735863.001]
  • [Cites] Lab Invest. 1983 Feb;48(2):224-30 [6823098.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):979-84 [11861522.001]
  • [Cites] Int J Exp Pathol. 2000 Apr;81(2):145-57 [10762442.001]
  • (PMID = 17080250.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitogens; 06LU7C9H1V / Triiodothyronine; 075T165X8M / Thioacetamide
  •  go-up   go-down


20. Sańko-Resmer J, Paczek L, Wyzgał J, Ziółkowski J, Ciszek M, Alsharabi A, Grzelak I, Paluszkiewicz R, Patkowski W, Krawczyk M: Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation. Transplant Proc; 2006 Jan-Feb;38(1):212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation.
  • As more effective therapies prolong the lives of patients with cystic fibrosis, there are now more patients in this population diagnosed with liver diseases.
  • Liver transplantation is an accepted method of treatment for children with cystic fibrosis and portal hypertension.
  • We present our first case of orthotopic liver transplantation performed in a 29-year-old man with cystic fibrosis.
  • [MeSH-major] Cystic Fibrosis / diagnosis. Liver Cirrhosis, Biliary / etiology. Liver Cirrhosis, Biliary / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male. Treatment Outcome


21. Aller MA, Arias JL, García-Domínguez J, Arias JI, Durán M, Arias J: Experimental obstructive cholestasis: the wound-like inflammatory liver response. Fibrogenesis Tissue Repair; 2008;1(1):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental obstructive cholestasis: the wound-like inflammatory liver response.
  • Obstructive cholestasis causes hepatic cirrhosis and portal hypertension.
  • The pathophysiological mechanisms involved in the development of liver disease are multiple and linked.
  • The early liver interstitial alterations described in these experimental models would produce an ischemia/reperfusion phenotype with oxidative and nitrosative stress.
  • This histopathological finding is also associated with fibrosis.It is proposed that the sequence of these inflammatory phenotypes, perhaps with a trophic meaning, ultimately produces a benign tumoral biliary process - although it poses severe hepatocytic insufficiency.
  • Moreover, the persistence of this benign tumor disease would induce a higher degree of dedifferentiation and autonomy and, therefore, its malign degeneration.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2005 Oct;20(10):1538-44 [16174071.001]
  • [Cites] Surgery. 1997 Aug;122(2):281-6; discussion 286-7 [9288133.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):535-44 [9314132.001]
  • [Cites] Microsc Res Tech. 1997 Sep 15;38(6):552-70 [9330346.001]
  • [Cites] Gen Pharmacol. 1997 Apr;28(4):525-9 [9147020.001]
  • [Cites] Lab Invest. 1997 Jun;76(6):765-78 [9194853.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):165-72 [9066647.001]
  • [Cites] Hepatology. 1996 Apr;23(4):888-95 [8666346.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):688-9 [8916885.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1118-24 [8831608.001]
  • [Cites] J Hepatol. 1995 Aug;23(2):235 [7499802.001]
  • [Cites] Hepatology. 1993 May;17(5):908-14 [8387951.001]
  • [Cites] J Hepatol. 1993 Feb;17(2):155-62 [8445230.001]
  • [Cites] Scand J Gastroenterol. 1993 Jan;28(1):10-4 [8430270.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1157-68 [10833491.001]
  • [Cites] Microsurgery. 2008;28(5):361-6 [18561272.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G357-66 [18511741.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1101-10 [18243041.001]
  • [Cites] Transplantation. 2008 Apr 27;85(8):1159-66 [18431237.001]
  • [Cites] Surgery. 2008 May;143(5):667-78 [18436015.001]
  • [Cites] Br J Surg. 2008 May;95(5):646-56 [18196571.001]
  • [Cites] J Surg Res. 2008 May 15;146(2):262-70 [18061617.001]
  • [Cites] Surgery. 2008 Mar;143(3):334-42 [18291254.001]
  • [Cites] Curr Opin Immunol. 2008 Feb;20(1):68-74 [18068343.001]
  • [Cites] Surgery. 2008 Mar;143(3):434-40 [18291265.001]
  • [Cites] Mutat Res. 2008 Jan-Feb;658(1-2):28-41 [17602853.001]
  • [Cites] Theor Biol Med Model. 2007;4:44 [17999758.001]
  • [Cites] Physiol Rev. 2008 Jan;88(1):125-72 [18195085.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):249-56 [18083132.001]
  • [Cites] Transplant Proc. 2007 Dec;39(10):3424-8 [18089397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50 [18032601.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1147-54 [17932231.001]
  • [Cites] Hepatology. 2007 Dec;46(6):1893-906 [17918268.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Nov 10;59(13):1351-65 [17804111.001]
  • [Cites] Dig Dis Sci. 2007 Dec;52(12):3348-54 [17436097.001]
  • [Cites] Semin Liver Dis. 2007 Nov;27(4):339-50 [17979071.001]
  • [Cites] Mol Cells. 2007 Oct 31;24(2):153-66 [17978567.001]
  • [Cites] J Transl Med. 2007;5:44 [17892556.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:435-61 [17506690.001]
  • [Cites] Comp Hepatol. 2007;6:7 [17663771.001]
  • [Cites] World J Surg. 2007 Oct;31(10):2023-32 [17665241.001]
  • [Cites] Comp Hepatol. 2007;6:1 [17311678.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G639-46 [17068118.001]
  • [Cites] Clin Sci (Lond). 2007 Mar;112(5):265-80 [17261089.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:55-8 [17282109.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):415-31 [17241889.001]
  • [Cites] Adv Clin Chem. 2007;43:1-57 [17249379.001]
  • [Cites] Dig Dis Sci. 2006 Dec;51(12):2248-56 [17103041.001]
  • [Cites] World J Gastroenterol. 2006 Dec 14;12(46):7413-20 [17167827.001]
  • [Cites] Inflamm Allergy Drug Targets. 2006 Dec;5(4):257-60 [17168797.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2006 Nov-Dec;54(6):367-74 [17122884.001]
  • [Cites] Clin Liver Dis. 2006 Aug;10(3):459-79, vii-viii [17162223.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6835-41 [17106933.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6577-84 [17075968.001]
  • [Cites] Med Sci Monit. 2006 Oct;12(10):RA225-34 [17006415.001]
  • [Cites] Pathophysiology. 2006 Dec;13(4):227-32 [16963238.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1567-76 [17071581.001]
  • [Cites] Med Hypotheses. 2007;68(1):202-9 [16963191.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G575-83 [16710052.001]
  • [Cites] Exp Toxicol Pathol. 2006 Aug;58(1):49-58 [16617007.001]
  • [Cites] Eur J Cell Biol. 2006 Aug;85(8):699-715 [16822580.001]
  • [Cites] Transplantation. 2006 Jul 27;82(2):258-66 [16858290.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G307-17 [16574985.001]
  • [Cites] World J Gastroenterol. 2006 Jun 14;12(22):3553-63 [16773712.001]
  • [Cites] World J Gastroenterol. 2006 Jun 14;12(22):3471-80 [16773704.001]
  • [Cites] J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):327-31 [16763895.001]
  • [Cites] FASEB J. 2006 May;20(7):811-27 [16675838.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1141-9 [16466825.001]
  • [Cites] FASEB J. 2006 May;20(7):828-32 [16675839.001]
  • [Cites] Pathophysiology. 2006 May;13(2):111-7 [16542827.001]
  • [Cites] J Hepatol. 2006 May;44(5):947-55 [16310280.001]
  • [Cites] J Cell Mol Med. 2007 Mar-Apr;11(2):176-205 [17488472.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):810-22 [16530521.001]
  • [Cites] J Hepatol. 2006 Mar;44(3):552-9 [16310277.001]
  • [Cites] J Endocrinol. 2006 Feb;188(2):345-54 [16461560.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Feb;316(2):592-600 [16221737.001]
  • [Cites] Trends Immunol. 2005 Dec;26(12):637-43 [16214414.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6079-84 [16273630.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1425-33 [10573521.001]
  • [Cites] Hepatology. 1999 Nov;30(5):1198-205 [10534341.001]
  • [Cites] Dig Dis Sci. 2007 Oct;52(10):2601-9 [17429735.001]
  • [Cites] Perit Dial Int. 2007 Jun;27 Suppl 2:S104-9 [17556287.001]
  • [Cites] Surg Oncol. 2006 Dec;15(4):235-42 [17400443.001]
  • [Cites] Mol Cancer. 2007;6:29 [17437633.001]
  • [Cites] Curr Opin Gastroenterol. 2007 May;23(3):299-305 [17414846.001]
  • [Cites] J Hepatol. 2007 May;46(5):797-803 [17321632.001]
  • [Cites] Free Radic Biol Med. 2007 Apr 15;42(8):1278-89 [17382208.001]
  • [Cites] Free Radic Biol Med. 2007 May 1;42(9):1381-91 [17395011.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(4):695-714 [17110155.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):583-6 [17313989.001]
  • [Cites] Eur J Pharmacol. 2007 Mar 29;560(1):61-8 [17292345.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):539-48 [17332881.001]
  • [Cites] Surgery. 2005 Aug;138(2):236-45 [16153432.001]
  • [Cites] J Nippon Med Sch. 2005 Aug;72(4):217-25 [16113492.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):223-8 [15937911.001]
  • [Cites] Exp Toxicol Pathol. 2005 Mar;56(4-5):273-80 [15816356.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):209-18 [15690074.001]
  • [Cites] Braz J Med Biol Res. 2005 Jan;38(1):127-32 [15665999.001]
  • [Cites] Inflamm Res. 2004 Dec;53(12):644-52 [15654511.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):121-37 [15633129.001]
  • [Cites] Microsurgery. 2004;24(6):442-7 [15389969.001]
  • [Cites] Ann Rheum Dis. 1954 Jun;13(2):102-8 [13171803.001]
  • [Cites] Rev Can Biol. 1953 Oct;12(2):155-75 [13121623.001]
  • [Cites] Rev Esp Enferm Dig. 1999 May;91(5):365-73 [10362878.001]
  • [Cites] J Hepatol. 1999 Apr;30(4):646-52 [10207806.001]
  • [Cites] J Hepatol. 1991;13 Suppl 4:S87-9 [1822520.001]
  • [Cites] Trends Neurosci. 1989 Mar;12(3):94-101 [2469224.001]
  • [Cites] Am Surg. 1985 May;51(5):245-51 [3888015.001]
  • [Cites] Scand J Gastroenterol. 1985 May;20(4):428-32 [4023608.001]
  • [Cites] Gastroenterology. 1990 Aug;99(2):466-77 [1694804.001]
  • [Cites] Br J Exp Pathol. 1984 Jun;65(3):305-11 [6743531.001]
  • [Cites] Fed Proc. 1983 Apr;42(6):1662-6 [6832383.001]
  • [Cites] Ann N Y Acad Sci. 1975 Apr 15;244:533-52 [1094885.001]
  • [Cites] Med Electron Microsc. 2004 Sep;37(3):141-8 [15449105.001]
  • [Cites] J Clin Invest. 2004 Aug;114(3):322-9 [15286798.001]
  • [Cites] J Invest Surg. 2004 Mar-Apr;17(2):99-104 [15204716.001]
  • [Cites] Med Hypotheses. 2004;63(1):42-6 [15193345.001]
  • [Cites] Ann Hepatol. 2003 Oct-Dec;2(4):159-63 [15115954.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):353-72 [15123075.001]
  • [Cites] Semin Liver Dis. 2004 Feb;24(1):21-42 [15085484.001]
  • [Cites] Eur J Clin Invest. 2004 Apr;34(4):290-6 [15086361.001]
  • [Cites] Acta Physiol Scand. 2004 Feb;180(2):177-85 [14738476.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Feb;229(2):170-81 [14734796.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):14-23 [14672609.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Dec 15;168(12):1421-6 [14668256.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9274-9 [12883003.001]
  • [Cites] Hepatology. 2003 Aug;38(2):355-63 [12883479.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):372-80 [12715172.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):337-76 [12663862.001]
  • [Cites] News Physiol Sci. 2003 Apr;18:65-70 [12644622.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Oct;11(4):849-64 [12607575.001]
  • [Cites] J Biomed Sci. 2003 Mar-Apr;10(2):170-8 [12595753.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] J Am Coll Surg. 2002 Jun;194(6):731-9 [12081063.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):200-9 [11830331.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1239-44 [11290541.001]
  • [Cites] Clin Liver Dis. 1999 Aug;3(3):465-75 [11291234.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2000 Dec;127(3):243-9 [11246495.001]
  • [Cites] Liver. 2000 Oct;20(5):387-96 [11092257.001]
  • [Cites] Mol Aspects Med. 2000 Jun;21(3):49-98 [10978499.001]
  • [Cites] J Cell Biol. 2000 Jul 24;150(2):F89-96 [10908592.001]
  • (PMID = 19014418.001).
  • [ISSN] 1755-1536
  • [Journal-full-title] Fibrogenesis & tissue repair
  • [ISO-abbreviation] Fibrogenesis Tissue Repair
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637833
  •  go-up   go-down


22. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


23. Natsume T, Okazumi S, Takayama W, Takeda A, Iwasaki K, Makino H, Sasagawa S, Cho A, Kouno T, Kondo S, Sunouchi K, Asano T, Ochiai T: Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT. Hepatogastroenterology; 2007 Sep;54(78):1745-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT.
  • BACKGROUND/AIMS: This study aimed to measure hepatic blood flow increase in cases with liver metastasis and to diagnose minimal metastasis which cannot be visualized by imaging modalities.
  • METHODOLOGY: The evaluation of hepatic arterial flow increase was performed quantitatively by newly devised index ELR (early-late-ratio) using dynamic computed tomographic (CT) scanning with contrast media.
  • RESULTS: The ratio of the cases with liver metastasis was significantly higher than that of normal liver control.
  • It was revealed that the ratio was correlated with microvessel proliferation in the liver around the metastasis by examination of surgical specimen.
  • CONCLUSIONS: ELR not only was useful to evaluate hepatic blood flow increase in the cases with liver metastasis but also could be applied to predict the patent group with micrometastasis.
  • [MeSH-major] Liver / blood supply. Liver Neoplasms / blood supply. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Regional Blood Flow. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Blood Flow Velocity. Case-Control Studies. Cell Proliferation. Densitometry. Hepatic Artery / pathology. Humans. Microcirculation. Neoplasm Metastasis. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019709.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


24. Erdogan D, van Delden OM, Busch OR, Gouma DJ, van Gulik TM: Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol; 2007 Nov-Dec;30(6):1252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas.
  • Hepatocellular adenomas (HCAs) are benign liver lesions which may be complicated by spontaneous intratumoral bleeding, with or without rupture into the abdominal cavity, or malignant degeneration.
  • Recent advances in radiological interventional techniques now offer selective transcatheter arterial embolization (TAE) as an alternative approach to surgery as the initial treatment to stop the bleeding or as an elective treatment to reduce the tumor mass of the HCA.
  • In two patients in whom the bleeding stopped spontaneously, TAE was electively undertaken 1 year after presentation to reduce the tumor mass of HCAs >5 cm.
  • Selective TAE may also be used as an elective treatment to reduce the tumor mass of larger HCAs.
  • [MeSH-major] Adenoma, Liver Cell / complications. Embolization, Therapeutic / methods. Hemorrhage / therapy. Liver Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605070.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Terán A, Casafont F, Fábrega E, Martínez-Taboada VM, Rodríguez-Valverde V, Pons-Romero F: [Adult-onset Still's disease with liver failure requiring liver transplantation]. Gastroenterol Hepatol; 2009 Dec;32(10):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset Still's disease with liver failure requiring liver transplantation].
  • [Transliterated title] Enfermedad de Still del adulto con desarrollo de insuficiencia hepática que precisa trasplante hepático.
  • We present the case of a 23-year-old man with fever of unknown origin, who developed acute liver failure 2 months after symptom onset, requiring an urgent liver transplantation.
  • The diagnosis of adult-onset Still's disease was established after the reappearance of symptoms after transplantation, and high doses of corticosteroids were used to control disease activity.
  • [MeSH-major] Liver Failure / etiology. Liver Transplantation. Still's Disease, Adult-Onset / surgery


26. Heilmaier C, Sutter R, Lutz AM, Seifert B, Willmann JK: [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session]. Rofo; 2008 May;180(5):440-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session].
  • [Transliterated title] Dynamische MRT der leber mit paralleler akquisitionstechnik: charakterisierung fokaler leberläsionen und analyse des gefässstatus in einem untersuchungsgang.
  • PURPOSE: To retrospectively evaluate the performance of breath-hold contrast-enhanced 3D dynamic parallel gradient echo MRI (pMRT) for the characterization of focal liver lesions (standard of reference: histology) and for the analysis of hepatic vasculature (standard of reference: contrast-enhanced 64-detector row computed tomography;.
  • MATERIALS AND METHOD: Two blinded readers independently analyzed preoperative pMRT data sets (1.5T-MRT) of 45 patients (23 men, 22 women; 28 - 77 years, average age, 48 years) with a total of 68 focal liver lesions with regard to image quality of hepatic arteries, portal and hepatic veins, presence of variant anatomy of the hepatic vasculature, as well as presence of portal vein thrombosis and hemodynamically significant arterial stenosis.
  • In addition, both readers were asked to identify and characterize focal liver lesions.
  • RESULTS: Based on histology, the 68 liver lesions were found to be 42 hepatocellular carcinomas (HCC), 20 metastases, 3 cholangiocellular carcinomas (CCC) as well as 1 dysplastic nodule, 1 focal nodular hyperplasia (FNH) and 1 atypical hemangioma.
  • Overall, the diagnostic accuracy was high for both readers (91 - 100 %) in the characterization of these focal liver lesions with an excellent interobserver agreement (kappa-values of 0.89 [metastases], 0.97 [HCC] and 1 [CCC]).
  • Anatomical variants of the hepatic arteries, hepatic veins and portal vein as well as thrombosis of the portal vein were reliably detected by pMRT.
  • It allows reliable detection and characterization of focal liver lesions as well as the depiction of hepatic vascular variants, portal vein thrombosis, and arterial stenosis.
  • Introducing pMRT in routine liver MRI may be another step towards a simplified diagnostic work-up prior to liver surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Liver / blood supply. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Arterial Occlusive Diseases / diagnosis. Bile Duct Neoplasms / blood supply. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Female. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Hepatic Artery / pathology. Hepatic Veins / pathology. Humans. Male. Middle Aged. Observer Variation. Portal Vein / pathology. Retrospective Studies. Sensitivity and Specificity. Thrombosis / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438745.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Polacco M, Vitale A, Valmasoni M, D'Amico F, Gringeri E, Brolese A, Zanus G, Neri D, Carraro A, Pauletto A, Romanelli E, Lo Bello S, Cillo U: Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report. Transplant Proc; 2010 May;42(4):1378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report.
  • Tumor progression before orthotopic liver transplantation (OLT) is the main cause of dropouts from waiting lists among patients with hepatocellular carcinoma (HCC).
  • Performing a porto-caval shunt (PCS) before parenchymal liver transection has the potential to allow an extended hepatectomy in patients with decompensated liver cirrhosis, reducing portal hyperflow and therefore the sinusoidal shear-stress on the remnant liver.
  • We report the case of a 59-year-old man affected by hepatitis C virus (HCV)-related decompensated liver cirrhosis (Child Pugh score presentation, C-10; Model for End Stage Liver Disease score, 18) and HCC (2 lesions of 2 and 2.8 cm).
  • The patient began the evaluation to join the OLT waiting list, but, in the 3 months required to complete the evaluation, he developed tumor progression: 3 HCC lesions, the largest 1 with a diameter of about 4.4 cm.
  • After appropriate preoperative studies, the patient underwent a major liver resection (trisegmentectomy) after side-to-side PCS by interposition of an iliac vein graft from a cadaveric donor.
  • Associating a partial side-to-side PCS with hepatic resection may represent a potential salvage therapy for patients with decompensated cirrhosis and HCC progression beyond listing criteria for OLT.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Portasystemic Shunt, Transjugular Intrahepatic / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534307.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


28. Zurbuchen U, Holmer C, Lehmann KS, Stein T, Roggan A, Seifarth C, Buhr HJ, Ritz JP: Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours. Int J Hyperthermia; 2010 Feb;26(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours.
  • INTRODUCTION: Knowledge about the changes in the electric conductivity during the coagulation process of radiofrequency ablation of the liver is a prerequisite for the predictability of produceable thermonecrosis in the liver.
  • MATERIALS AND METHODS: Continuous measurements of the electric conductivity sigma in ex vivo porcine liver (n = 25) were done during the coagulation and cooling process at the temperature range of the radiofrequency ablation at a frequency of 470 kHz relevant for the radiofrequency ablation.
  • Measurements of the electric conductivity were performed in both perfused porcine liver (n = 3) and a human surgical specimen from a colorectal liver metastasis.
  • At 37 degrees C, the specific conductance sigma in the healthy perfused porcine liver was 0.52 S/m, 0.55 S/m and 0.57 S/m (mean 0.55 S/m).
  • The electric conductivity of the human colorectal liver metastasis was clearly higher.
  • [MeSH-major] Catheter Ablation / methods. Electric Conductivity. Liver / physiopathology. Liver Neoplasms / physiopathology
  • [MeSH-minor] Animals. Colorectal Neoplasms / pathology. Humans. Swine. Temperature

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20100050.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Culafić DM, Lekić NS, Kerkez MD, Mijac DD: Liver actinomycosis mimicking liver tumour. Vojnosanit Pregl; 2009 Nov;66(11):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver actinomycosis mimicking liver tumour.
  • BACKGROUND: The liver actinomycosis is a rare disease associated with complex differentiation from the liver metastases or hepatocellular carcinoma.
  • Diagnostic procedures that followed, including abdominal ultrasound and computed tomography led us to the diagnosis of metastatic liver disease of unknown etiology with pleural and pericardial effusion.
  • Intraoperatively, the presence of liver pseudotumor without malignancy in the liver was confirmed.
  • Histological examination confirmed the diagnosis of liver actinomycosis.
  • CONCLUSION: Liver actinomycosis has a nonspecific presentation, often mimicking liver tumor.
  • A timely diagnosis as well as a combined surgical and antibiotic therapy is necessary in the treatment of patients with primary disease and prevention of complications.
  • [MeSH-major] Actinomycosis / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Middle Aged


30. Yuan Y, Song B, Wu B, Xu J, Li YC: [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;38(3):526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation].
  • OBJECTIVE: To investigate the relationship between the donor liver volume calculated by 16-slice multi-detector-row CT before living related liver transplantation (LRLT) and the hepatic weight measured during the operation, and try to get an equation to express the relation of associating volume with weight of transplanted liver.
  • The imaging data at the hepatic venous phase was used for whole and partial liver volumetry processed or measured on a dedicated image post-processing workstation.
  • The resected part of donor liver was weighed during the operation.
  • Statistical analysis was used to test the relationship between the CT-measured liver volume and the actual weight of resected liver part, and the relationship was expressed by scatter graph and linear equation.
  • RESULTS: The mean of liver volumes calculated by CT before operation was (699. 47 +/- 140.
  • 18) mL, the mean weight of donated livers measured during operation was (532. 14+/- 98.
  • CONCLUSION: The correlation equation between the donor liver volume calculated by CT preoperatively and the grafted liver weight measured during operation can be used to accurately estimate the desired liver mass for LRLT, which is very helpful for donor selection and preoperative planning.
  • [MeSH-major] Liver / anatomy & histology. Liver / radiography. Liver Transplantation. Living Donors. Preoperative Period. Tomography, X-Ray Computed


36. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, Bonino F, Brunetto MR: Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol; 2008 Oct 28;14(40):6154-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
  • AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a rapid non-invasive technique to evaluate liver fibrosis, in the management of chronic hepatitis B virus (HBV) carriers.
  • METHODS: In 297 consecutive HBV carriers, we studied the correlation between liver stiffness (LS), stage of liver disease and other factors potentially influencing FS measurements.
  • We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of fibrosis >or= S3 and cirrhosis respectively, showing 93.9% and 86.5% sensitivity, 88.5% and 96.3% specificity, 76.7% and 86.7% positive predictive value (PPV), 97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic accuracy.
  • CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV carriers, provided that the pattern of biochemical activity is taken into account.
  • In the inactive carrier, it identifies non-HBV-related causes of liver damage and transient reactivations.
  • In CHB patients, it may warrant a more appropriate timing of control liver biopsies.
  • [MeSH-major] Alanine Transaminase / blood. Carrier State. Clinical Enzyme Tests. Elasticity Imaging Techniques. Hepatitis B / diagnosis. Hepatitis B, Chronic / diagnosis. Liver / pathology. Liver Cirrhosis / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003;39 Suppl 1:S3-25 [14708673.001]
  • [Cites] Ultrasound Med Biol. 2003 Dec;29(12):1705-13 [14698338.001]
  • [Cites] J Viral Hepat. 1996 Nov;3(6):277-83 [8947878.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Hepatology. 2005 Jan;41(1):48-54 [15690481.001]
  • [Cites] Hepatology. 2005 Oct;42(4):838-45 [16121354.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9 [16394849.001]
  • [Cites] Gut. 2006 Mar;55(3):403-8 [16020491.001]
  • [Cites] Semin Liver Dis. 2006 May;26(2):130-41 [16673291.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1511-7 [17133503.001]
  • [Cites] Hepatology. 2007 Feb;45(2):507-39 [17256718.001]
  • [Cites] J Viral Hepat. 2007 May;14(5):360-9 [17439526.001]
  • [Cites] Gut. 2007 Jul;56(7):968-73 [17255218.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1057-70 [17654702.001]
  • [Cites] Hepatology. 2008 Feb;47(2):380-4 [18095306.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):263-70 [11830339.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2002 Apr;49(4):436-46 [11989699.001]
  • [Cites] Gut. 2003 Mar;52(3):416-9 [12584226.001]
  • [Cites] Gut. 2003 Mar;52(3):420-4 [12584227.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Mar;18(3):246-52 [12603523.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2261-7 [14572577.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • (PMID = 18985805.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2761576
  •  go-up   go-down


37. Wang D, Dou K, Xiang H, Song Z, Zhao Q, Chen Y, Li Y: Involvement of RhoA in progression of human hepatocellular carcinoma. J Gastroenterol Hepatol; 2007 Nov;22(11):1916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The intratumor expression level of Rho was determined and compared with that in adjacent non-cancerous hepatic tissue using quantitative real time RT-PCR and Western blotting in 64 patients with HCC.
  • RESULTS: RhoA immunostaining was strong in malignant tissue whereas it was minimal in benign tissue.
  • Tumor tissue of HCC patients demonstrated a copy number of RhoA mRNA that was well correlated with its protein level in each case and was significantly higher than that found in the corresponding non-cancerous liver tissue (P < 0.01).
  • CONCLUSIONS: This is the first demonstration that the expression level of RhoA is correlated with tumor progression and metastasis in HCC.
  • RhoA in tumor tissue might be expected to be not only a good candidate marker for invasive and proliferative tumor cells, but also a molecular target of these cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. rhoA GTP-Binding Protein / analysis
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Polymerase Chain Reaction. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914970.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 124671-05-2 / RHOA protein, human; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


38. Bilbao I, Castro E, Dopazo C, Castro S, Allende E, Genesca J, Tallada N, Quiroga S, Margarit C: [Hepatic angiomyolipoma in two patients infected with hepatitis C virus]. Gastroenterol Hepatol; 2007 Apr;30(4):222-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatic angiomyolipoma in two patients infected with hepatitis C virus].
  • [Transliterated title] Angiomiolipoma hepático en dos pacientes con infección por el virus de la hepatitis C.
  • AIM: The aim of this study is to present our experience with two cases of hepatic angiomyolioma in hepatitis C virus (HCV) positive patients, and to up-date the clinical manage, diagnostic and treatment of this entity.
  • Histopathological examination and immunohistochemical findings gave the diagnosis of angiomyolipoma.
  • At time of diagnosis the size of tumours was 4.8 and 8 cm of diameter.
  • DISCUSSION AND CONCLUSION: The hepatic angiomyolipoma is a rare benign tumour, mimicking other liver tumours.
  • Although no patognomonic features, there are some radiological findings that point out to the diagnosis of angiomy olipoma.
  • Nevertheless, definitive diagnosis is done by his tological and immunohistochemical findings (HMB-45).
  • The hepatic angiomyolipoma consists of varing proportion of three elements, mature fat cells, smooth muscle cells and blood vessels.
  • Although it is a benign tumour, the difficulty in ruling out malignancy, prompted surgical management.
  • [MeSH-major] Angiomyolipoma / complications. Hepatitis C, Chronic / complications. Liver Neoplasms / complications
  • [MeSH-minor] Adipocytes / pathology. Antigens, Neoplasm. Biomarkers, Tumor / analysis. Comorbidity. Diagnosis, Differential. Female. Hepatectomy. Humans. Incidental Findings. Melanoma-Specific Antigens. Middle Aged. Myocytes, Smooth Muscle / pathology. Neoplasm Proteins / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408551.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 33
  •  go-up   go-down


39. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I: Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol; 2006 08;21(8):857-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
  • VEGF exerts its action by binding to the specific cell surface receptors, fms-like tyrosine kinase 1 (Flt-1) and fetal liver kinase 1 (FLK/KDR).
  • In tumor angiogenesis, Vascular endothelial growth factor stimulates endothelial cells to produce Basic fibroblastic growth factor (bFGF), which further enhances angiogenic activity.
  • Herein, we evaluate the expression of these angiogenic factors and receptors in normal prostate, high grade prostate intraepithelial neoplasia (HGPIN) and prostatic cancer (CaP).
  • [MeSH-major] Adenocarcinoma / pathology. Angiogenic Proteins / metabolism. Microcirculation. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology. Receptors, Vascular Endothelial Growth Factor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Fibroblast Growth Factor 2 / metabolism. Humans. Immunohistochemistry. Male. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691538.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


40. Zhong G, Hu J, Chen Z, Luo Y, Zhang Y, Yin Y, Li W, Yi Z, Chen G: [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jan;35(1):70-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG].
  • OBJECTIVE: To explore the molecular mechanism of the formulae for calming the liver and suppressing YANG in migraine rat model with syndrome of hyperactivity of the liver-YANG.
  • METHODS: A rat model of migraine with hyperactivity of liver-YANG was established through electrical trigeminal ganglion stimulation and syndrome of oral administration of Fuzi decoction.
  • The total proteins of the lymphocyte in the rats were separated by immobilized pH gradient-based 2-dimensional gel electrophoresis (2-DE), and the 2-DE image was analyzed by PDQuest 7.0 software.
  • RESULTS: The formulae for calming the liver and suppressing YANG could also improve headache.
  • Well-resolution and reproducible 2-DE patterns of rat lymphocyte from normal, model, and therapy tissues were obtained.
  • CONCLUSION: Differences occur in the expression of lymphocyte proteins in migraine rats with syndrome of hyperactivity of liver-YANG after treatment with the formulae for calming the liver and suppressing YANG, and the 11 identified protein spots may be associated with its mechanism.
  • [MeSH-minor] Animals. Diagnosis, Differential. Drugs, Chinese Herbal / therapeutic use. Electric Stimulation. Liver / physiopathology. Male. Proteins / analysis. Proteins / metabolism. Rats. Rats, Sprague-Dawley. Yin-Yang

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130367.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Proteins; 0 / Proteome
  •  go-up   go-down


41. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, Saini S: Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol; 2005 Jul;185(1):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
  • OBJECTIVE: The objective of our study was to assess the relative performance of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET for the detection of liver metastases from adenocarcinoma of the colon and pancreas.
  • MATERIALS AND METHODS: Imaging data of 34 patients (23 men, 11 women; age range, 44-78 years) with adenocarcinoma of the colon (n = 27) or adenocarcinoma of the pancreas (n = 7) who had undergone mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were retrospectively reviewed for the presence and number of liver metastases.
  • RESULTS: Thirty patients had hepatic metastases and four had no hepatic metastases according to the standard of reference.
  • MRI detected more hepatic metastases than FDG PET (p = 0.016).
  • CONCLUSION: In patients with colon and pancreatic adenocarcinoma, high-spatial-resolution mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were comparable in the detection of patients with liver metastases.
  • However, significantly more and smaller liver metastases were detected on MRI than on FDG PET.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972430.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42Z2K6ZL8P / Manganese; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


42. Burton JR Jr, Rosen HR: Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol; 2005 Jul;3(7):700-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States.
  • BACKGROUND & AIMS: Hepatitis C virus (HCV)-related liver failure is the leading indication for liver transplantation (LT).
  • To gain insight into how transplant centers are dealing with this issue and whether published prognostic factors are being used, we conducted a survey of liver transplant centers across the US in late 2003.
  • However, less than half thought international normalized ratio (INR), Model for End-Stage Liver Disease (MELD), and bilirubin were important factors.
  • [MeSH-major] Hepatitis C / surgery. Liver Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206504.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Yin Z, Wang X, Li N, Ni X, Jiang F, Li Y, Li J: Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation. Transplant Proc; 2006 Dec;38(10):3251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation.
  • BACKGROUND: We developed a new porcine model for auxiliary liver/small bowel transplantation (LSBT).
  • The possible immunological advantage on small bowel graft induced by simultaneously transplanted liver in the large animal was assessed.
  • CONCLUSIONS: An immunological advantage on intestinal graft can be induced by simultaneously transplanted liver in auxiliary LSBT.
  • The liver graft may reduce the risk of intestinal rejection and thus protect the bowel graft.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Intestine, Small / transplantation. Liver Transplantation / physiology. Transplantation, Homologous / physiology

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175239.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


44. Târcoveanu E, Vlad N, Moldovanu R, Georgescu St, Bradea C, Lupaşu C, Crumpei F, Vasilescu A, Strat V: [Pyogenic liver abscesses]. Chirurgia (Bucur); 2008 Jul-Aug;103(4):417-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pyogenic liver abscesses].
  • BACKGROUND: Pyogenic liver abscesses were a relative rare disease.
  • In the last decades the management of the liver abscesses was changed due to the new imaging and surgical techniques.
  • AIM: To evaluate the clinical features, imaging techniques and treatment of the liver abscesses.
  • RESULTS: Of the 71 patients with liver abscesses, 39 (54.9%) were included in group I and 32 (45.1%) in group II.
  • The male/female ratio was 49/22; liver abscesses were more frequent to the males, in group I (63.3%) and more frequent to the women, in group II (63.6%) (p = 0.035).
  • We noted, as associated disease: diabetes--16% (N = 12), liver cirrhosis--7% (N = 5), malignancies--4.2% (N = 3).
  • The etiology was diverse: 25.4% after hepatic hydatid cysts, 12.7% with biliary origin, 22.5% with hematogenous and phlebitis origin and 39.4% with unknown origin (cryptogenetic).
  • Treatment of the liver abscesses was surgical, by open (87.3%) or laparoscopic approach (8.5%), and percutaneous (ultrasound guided punction)--2.8%.
  • The intraoperative mean dimension of the liver abscesses was 74.26 +/- 4.35 mm (range 30-160), similar with dimensions measured by echography 72.29 +/- 4.84 mm (range 12-179)--p < 10(-3).
  • Univariate analysis revealed as prognosis factors for intraoperative bleeding, diameter of the liver abscess (p < 10(-3)), dimension of the residual cavity (p < 10(-3)) and the pus volume (p < 10(-3)).
  • CONCLUSIONS: Pyogenic liver abscess is a challenging disease with high rate of postoperative morbidity.
  • Most of the abscesses are unique and situated in the right lobe of the liver.
  • The imaging techniques, especially ultrasound exam and CT-scan, are essential for the diagnosis and the treatment of liver abscesses.
  • [MeSH-major] Hepatectomy. Liver Abscess, Pyogenic / microbiology. Liver Abscess, Pyogenic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780615.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


45. Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N: Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int; 2008 Dec;7(6):590-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection in liver transplant recipients.
  • BACKGROUND: Liver resection after liver transplantation is a relatively uncommon procedure.
  • Indications for liver resection include hepatic artery thrombosis (HAT), non-anastomotic biliary stricture (ischemic biliary lesions), liver abscess, liver trauma and recurrence of hepatocellular carcinoma (HCC).
  • METHODS: Eleven resections at a mean of 59 months after liver transplantation were made over 18 years.
  • Indications for liver resection included HCC recurrence in 4 patients, ischemic cholangiopathy, segmental HAT, sepsis and infected hematoma in 2 each, and ischemic segment IV after split liver transplantation in 1.
  • There were 3 deaths, two from HCC recurrence and one from post-transplant lymphoproliferative disorder.
  • CONCLUSIONS: Liver resection in liver transplant recipients is safe, and has good outcome in selected patients and avoids re-transplantation in the majority of patients.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Transplantation / statistics & numerical data. Postoperative Complications / mortality. Postoperative Complications / surgery
  • [MeSH-minor] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Child. Child, Preschool. Cholestasis / mortality. Cholestasis / surgery. Follow-Up Studies. Hospital Mortality. Humans. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation / mortality. Reoperation / statistics & numerical data. Thrombosis / mortality. Thrombosis / surgery


46. Vennarecci G, Ettorre GM, Lorusso R, Santoro R, Visco G, Santoro E: [Surgical prospects for liver metastases]. Chir Ital; 2007 Jan-Feb;59(1):27-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical prospects for liver metastases].
  • The recent advances in liver surgery have made it possible to perform liver resections in an increasing number of patients with consequent improvement in the results.
  • This coincides with an amplification of the indications to liver surgery for metastases.
  • Besides the development of radiological procedures as applied to liver surgery and more effective chemotherapy protocols, the actual approach to patients with liver metastases is shared by three figures - the surgeon, the radiologist and the oncologist.
  • Currently it has been shown that liver resections for metastases are possible with a meaningful increase of survival in the case of colorectal and neuroendocrine liver metastases and in selected cases of non-colorectal non-neuroendocrine metastases.
  • From the technical point of view the most remarkable aspect is the possibility of expanding the criteria of resectability by means of liver resections in one or two steps associated with portal vein embolisation or ligation of a portal branch.
  • It is also possible to perform iterative liver resections and liver transplantation in selected cases of neuroendocrine liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neuroendocrine Tumors / secondary. Neuroendocrine Tumors / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361929.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 67
  •  go-up   go-down


47. Tanikawa K, Torimura T: Studies on oxidative stress in liver diseases: important future trends in liver research. Med Mol Morphol; 2006 Mar;39(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on oxidative stress in liver diseases: important future trends in liver research.
  • Oxidative stress has recently been shown to play an important role in various liver diseases.
  • Therefore, further studies on oxidative stress in liver diseases are urgently required.
  • [MeSH-major] Biomedical Research / trends. Liver / pathology. Liver Diseases / metabolism. Liver Diseases / pathology. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1796-807 [14724832.001]
  • [Cites] Kurume Med J. 1964;11:177-81 [14301621.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):568-71 [11832470.001]
  • [Cites] Circulation. 2003 Jul 29;108(4):414-9 [12860911.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):307-12 [11201732.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):401-6 [9215123.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):599-605 [16024129.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2198-205 [10445550.001]
  • [Cites] Hepatol Res. 2005 Oct;33(2):97-9 [16216545.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):430-4 [10488700.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1399-410 [11984526.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):616-22 [11059866.001]
  • [Cites] J Clin Invest. 2000 Jul;106(2):171-6 [10903330.001]
  • [Cites] Gastroenterol Jpn. 1989 Dec;24(6):655-62 [2514117.001]
  • (PMID = 16575511.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


48. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C: Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism; 2010 Sep;59(9):1327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis.
  • Recent evidence has suggested an association between microalbuminuria and ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in patients with diabetes and prediabetes.
  • We thus evaluated the relationships between microalbuminuria and liver histology in a hospital-based sample of 87 adults with biopsy-proven NAFLD from Turkey.
  • There were no differences in the prevalence of microalbuminuria in patients with definite nonalcoholic steatohepatitis, borderline nonalcoholic steatohepatitis, and simple fatty liver.
  • [MeSH-major] Albuminuria / complications. Fatty Liver / complications. Liver / pathology. Liver Cirrhosis / complications

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Metabolism. 2010 Sep;59(9):E5; author reply E6 [20417942.001]
  • (PMID = 20096896.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, Zucman-Rossi J, Balabaud C, Saric J: Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology; 2009 Aug;50(2):481-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No differences were observed in solitary or multiple tumors in terms of hemorrhagic manifestations between groups.
  • Steatosis (tumor), microadenomas (resected specimen), and additional benign nodules were more frequently observed in HNF1alpha-inactivated HCAs (P < 0.01) than in IHCAs.
  • Body mass index > 25, peliosis (tumor), and steatosis in background liver were more frequent in IHCA (P < 0.01).
  • After incomplete resection (HCA left in nonresected liver), the majority of HCA remained stable in the two main groups and even sometimes regressed.
  • As a consequence, we believe that management of HCA needs to be adapted to the phenotype of these tumors.
  • [MeSH-major] Adenoma, Liver Cell / classification. Liver Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585623.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acid-Binding Proteins; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / Serum Amyloid A Protein; 0 / beta Catenin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


50. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N: Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol; 2008 Mar;18(3):486-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions.
  • The purpose of this study was to measure apparent diffusion coefficient values of normal liver parenchyma and focal liver lesions utilizing a respiratory gated diffusion sequence with multiple b-values and to investigate whether apparent diffusion coefficient (ADC) measurements may be utilized to characterize and differentiate between malignant and benign focal hepatic lesions.
  • Thirty-eight consecutive patients underwent MRI of the liver including diffusion-weighted imaging (DWI).
  • ADC values were recorded on corresponding maps utilizing region of interest measurements in patients with benign (group A), malignant (group B) focal lesions and liver parenchyma (group C).
  • No focal lesions were detected in 11 patients, with a mean ADC value (CI 95%) of liver parenchyma 1.25x10(-3) mm2/s (1.21x10(-3) mm2/s-1.29x10(-3) mm2/s).
  • Differences in mean ADC of liver parenchyma between group A and B were not significant (p=0.054, 1.30x10(-3) mm2/s and 1.31x10(-3) mm2/s, respectively).
  • Mean ADC value (95% CI) of 22 benign lesions found in 18 patients was 2.55x10(-3) mm2/s (2.35x10(-3) mm2/s-2.74x10(-3) mm2/s), while the mean ADC value (95% CI) of 16 malignant lesions recorded in 9 patients was 1.04x10(-3) mm2/s (0.9x10(-3) mm2/s-1.17x10(-3) mm2/s).
  • The difference between mean ADC values of benign and malignant focal lesions was statistically significant (p<0.0001).
  • Respiratory gated diffusion-weighted imaging in the liver is technically feasible.
  • Apparent diffusion coefficient measurements can be useful in differentiating malignant from benign focal liver lesions.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Respiration

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimaging. 2003 Oct;13(4):330-8 [14569825.001]
  • [Cites] J Ultrasound Med. 2004 Feb;23 (2):207-15 [14992357.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1111-20 [11000175.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1521-30 [17114546.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Radiology. 1999 Mar;210(3):617-23 [10207458.001]
  • [Cites] Clin Radiol. 2001 Feb;56(2):138-45 [11222073.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4175-9 [15736469.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):620-6 [15591461.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):146-52 [17139633.001]
  • [Cites] NMR Biomed. 1995 Nov-Dec;8(7-8):289-96 [8739267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Radiology. 2006 Jun;239(3):632-49 [16714455.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):423-9 [2161612.001]
  • [Cites] Radiology. 1997 Sep;204(3):739-44 [9280252.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):397-401 [11241813.001]
  • (PMID = 17994317.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Jin HB, Gu ZY, Yu CH, Li YM: Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int; 2005 Aug;4(3):389-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.
  • BACKGROUND: Nonalcoholic fatty liver disease (NAFLDéis a common chronic liver disease in China, of which diabetic fatty liver (DFLéaccounts for a large proportion in clinic.
  • DFL is a disease without specific clinical features and lacking of confirmatory laboratory tests, and the etiology of hepatic steatosis remains poorly understood.
  • The aim of this paper was to explore the clinical characteristics and to determine associated risk factors in type 2 diabetes patients with fatty liver.
  • CONCLUSIONS: Dyslipidemia, dysglycemia and elevation of liver enzyme can be seen more frequently in the DFL patients than in the NDFL patients.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Fatty Liver / blood. Fatty Liver / etiology
  • [MeSH-minor] Aged. Alanine Transaminase / blood. Blood Glucose / metabolism. Case-Control Studies. Cholesterol, HDL / blood. Enzymes / blood. Female. Humans. Lipids / blood. Liver / enzymology. Male. Middle Aged. Risk Factors. Triglycerides / blood


52. De Leeuw K, Woestenburg A, Verbeelen D: Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis. NDT Plus; 2008 Dec;1(6):412-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis.
  • But there has been ongoing concern about lanthanum accumulation in tissues, especially in liver.
  • We describe the case of a woman with pre-existing liver disease, who presented with acute liver failure after introduction of lanthanum carbonate to her treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S79-86 [15508107.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2809-13 [16316357.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):1062-9 [15698446.001]
  • [Cites] Semin Dial. 2006 May-Jun;19(3):195-9 [16689967.001]
  • [Cites] CNS Drugs. 2005;19(3):185-92 [15740174.001]
  • (PMID = 28657006.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; chronic renal failure / lanthanum carbonate / liver disease / phosphor
  •  go-up   go-down


53. Zhao X, Loo SC, Lee PP, Tan TT, Chu CK: Synthesis and cytotoxic activities of chloropyridylimineplatinum(II) and chloropyridyliminecopper(II) surface-functionalized poly(amidoamine) dendrimers. J Inorg Biochem; 2010 Feb;104(2):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic effects of the compounds against cells of neoplastic origin (MOLT-4, MCF-7) and cells of benign origin (Chang Liver) were studied.
  • Most notably, significant inhibitions were observed for 7E on all cell lines, in which its IC(50) values were 11.1+/-0.6, 10.2+/-1.5 and 8.7+/-0.7microM against MOLT-4, MCF-7 and Chang Liver cells respectively.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. Inorganic Chemicals / chemical synthesis. Inorganic Chemicals / chemistry. Inorganic Chemicals / pharmacology. Microscopy, Electron, Scanning. Models, Chemical. Molecular Structure. Nanoparticles / chemistry. Nanoparticles / ultrastructure. Platinum Compounds / chemical synthesis. Platinum Compounds / chemistry. Platinum Compounds / pharmacology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Spectrophotometry, Infrared

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. PLATINUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942292.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / Inorganic Chemicals; 0 / Platinum Compounds; 12648-47-4 / platinum chloride; 49DFR088MY / Platinum; 789U1901C5 / Copper
  •  go-up   go-down


54. Connolly G, Wladis E, Masselam K, Weinberg DA: Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma. Orbit; 2007 Dec;26(4):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent radiotherapy of the residual tumor at the left orbital apex, as well as radiotherapy of small liver and lung nodules felt to likely represent metastatic melanoma.
  • Five years later, he was still alive and well, with no further tumor demonstrable in the orbit, lung or liver.
  • We discuss some hypotheses that may explain such tumor behavior.
  • While melanoma is often considered a highly malignant and lethal tumor, some melanomas are characterized by a more benign course.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097971.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Wiegard C, Lohse AW: [Liver and rheumatism]. Z Rheumatol; 2005 Feb;64(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver and rheumatism].
  • [Transliterated title] Leber und Rheuma.
  • There are multiple relations between rheumatic diseases and the liver, nevertheless the liver is extremely rare involved in rheumatic diseases.
  • "Elevated liver enzymes" are quite often found in patients who are under the medication with immunosuppressive drugs or/and non-steroidal antirheumatics.
  • The most frequent cause for "elevated liver enzymes" are toxic and allergic side effects of drugs; however, in rare cases it might be extremely helpful to examine, whether an independent liver disease exists.
  • Underlying liver diseases which might be associated with the rheumatic disorder or exist accidentally may change the therapeutic management of the patient.
  • If the liver disease present can cause the rheumatic disorder (e. g. virus-induced vasculitis, hemochromatosis), a specific hepatological therapy should precede the immunosuppression.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Antirheumatic Agents / therapeutic use. Liver Diseases / complications. Liver Diseases / diagnosis. Rheumatic Diseases / complications. Rheumatic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metab Brain Dis. 2004 Dec;19(3-4):357-81 [15554428.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):551-65 [1411653.001]
  • [Cites] Semin Arthritis Rheum. 1992 Jun;21(6):376-86 [1626283.001]
  • [Cites] Q J Med. 1968 Jan;37(145):171-82 [5657764.001]
  • [Cites] Hepatology. 1990 May;11(5):730-4 [2347546.001]
  • [Cites] Nature. 1969 Aug 2;223(5205):472-6 [4894426.001]
  • [Cites] Intern Med. 2004 Mar;43(3):258-62 [15098613.001]
  • [Cites] J Hepatol. 1998 Mar;28(3):525-6 [9551696.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):234-6 [14505218.001]
  • [Cites] QJM. 2003 Nov;96(11):787-91 [14566034.001]
  • [Cites] J Viral Hepat. 2003 Jul;10 (4):298-305 [12823597.001]
  • [Cites] J Rheumatol. 2001 Nov;28(11):2466-73 [11708420.001]
  • [Cites] Medicine (Baltimore). 1980 Sep;59(5):367-79 [7432153.001]
  • [Cites] Curr Opin Rheumatol. 2004 Jan;16(1):62-6 [14673391.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):631-5 [11394667.001]
  • [Cites] Lupus. 1993 Aug;2(4):275-9 [8268978.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3317-26 [12483738.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):176-9 [11886966.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Oct;18(5):663-76 [15454125.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Aug;16(8):801-7 [15256984.001]
  • [Cites] Pediatr Dermatol. 2004 Sep-Oct;21(5):577-9 [15461767.001]
  • [Cites] Am J Pathol. 1978 Mar;90(3):619-32 [24342.001]
  • [Cites] Z Gastroenterol. 2003 Jun;41(6):517-22 [12806536.001]
  • (PMID = 15756497.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 28
  •  go-up   go-down


56. Rodríguez-Peláez M, Menéndez De Llano R, Varela M: [Benign liver tumors]. Gastroenterol Hepatol; 2010 May;33(5):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign liver tumors].
  • [Transliterated title] Tumores benignos del hígado.
  • There is a wide range of benign liver tumors that behave in very different ways and require a management strategy specifically tailored to each.
  • The most common benign solid liver tumor is hemangioma followed by focal nodular hyperplasia; the most common cystic tumor is the simple cyst.
  • Most of these tumors are asymptomatic and are discovered as incidental findings on imaging tests performed for other reasons.
  • The differential diagnosis with malignant liver tumors is sometimes difficult.
  • [MeSH-major] Adenoma / pathology. Cysts / pathology. Focal Nodular Hyperplasia / pathology. Hemangioma / pathology. Liver Diseases / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor. Carcinoma, Hepatocellular / diagnosis. Child. Diagnosis, Differential. Diagnostic Imaging. Female. Hepatectomy. Humans. Incidental Findings. Male. Mutation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Hepatol. 2010 Jun-Jul;33(6):473-4; author reply 474-5 [20537429.001]
  • (PMID = 20096966.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 31
  •  go-up   go-down


57. Chan SC, Lo CM, Ng KK, Fan ST: Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience. Am J Transplant; 2010 Apr;10(4):859-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience.
  • The issue of small-for-size graft (SFSG) containing the middle hepatic vein in right liver living donor liver transplantation from 1996 to 2008 (n = 320) was studied.
  • Characteristics of donors, grafts and recipients were comparable between Era I (first 50 cases) and Era II (next 270 cases) except that the median model for end-stage liver disease (MELD) score was higher in Era I (29 vs. 24; p = 0.024).
  • The median graft to standard liver volume ratio (G/SLV) in Era I was 49.0% (range, 32.8-86.2%), versus 49.3% (range, 28.4-89.4%) in Era II (p = 0.498).
  • [MeSH-major] Liver Transplantation. Living Donors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148811.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Abboud G, Kaplowitz N: Drug-induced liver injury. Drug Saf; 2007;30(4):277-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced liver injury.
  • Drug-induced liver injury is a frequent cause of hepatic dysfunction.
  • Reliably establishing whether the liver disease was caused by a drug requires the exclusion of other plausible causes and the search for a clinical drug signature.
  • The drug signature consists of the pattern of liver test abnormality, the duration of latency to symptomatic presentation, the presence or absence of immune-mediated hypersensitivity and the response to drug withdrawal.
  • Determination of causality also includes an evaluation of individual susceptibility to drug-induced liver injury.
  • Components of the drug signature in conjunction with certain risk factors have been incorporated into formal scoring systems that are predictive of the likelihood of drug-induced liver injury.
  • Mitigating the potential for drug-induced liver injury is achieved by the identification of toxicity signals during clinical trials and the monitoring of liver tests in clinical practice.
  • There are three signals of liver toxicity in clinical trials: (i) a statistically significant doubling (or more) in the incidence of serum alanine aminotransferase (ALT) elevation >3 x the upper limit of normal (ULN);.
  • Monitoring of liver tests in clinical practice has shown unconvincing efficacy, but where a benefit-risk analysis would favour continued therapy, monthly monitoring may have some benefit compared with no monitoring at all.
  • With rare exception, treatment of drug-induced liver injury is principally supportive.
  • Drug toxicity is the most common cause of acute liver failure, defined as a prolonged prothrombin time (international normalised ratio > or =1.5) and any degree of mental alteration occurring <26 weeks after the onset of illness in a patient without pre-existing cirrhosis.
  • A patient who meets these criteria must be evaluated for liver transplantation.
  • The pathogenesis of drug-induced liver injury can be examined on the basis of the two principal patterns of injury.
  • [MeSH-major] Chemical and Drug Induced Liver Injury. Drug-Related Side Effects and Adverse Reactions. Liver Diseases / diagnosis
  • [MeSH-minor] Animals. Drug Monitoring / methods. Humans. Liver / drug effects. Liver / pathology. Liver / physiopathology. Liver Function Tests. Models, Biological. Pharmaceutical Preparations / administration & dosage. Risk Factors

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Res Toxicol. 2001 Feb;14 (2):175-81 [11258966.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1425-34 [12774022.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):923-34 [9041255.001]
  • [Cites] JAMA. 1999 Mar 17;281(11):1014-8 [10086436.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S44-8 [14986274.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):694-701 [11409940.001]
  • [Cites] Am J Med. 2003 Mar;114(4):299-306 [12681458.001]
  • [Cites] Hepatology. 2004 May;39(5):1430-40 [15122773.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):916-7 [9518284.001]
  • [Cites] Anesth Analg. 2002 Feb;94(2):243-9, table of contents [11812677.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 24;226(3):695-702 [8831677.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4333-40 [7722291.001]
  • [Cites] JAMA. 2002 May 1;287(17):2273-5 [11980528.001]
  • [Cites] Gut. 1989 Apr;30(4):515-9 [2714684.001]
  • [Cites] Clin Exp Allergy. 1998 Sep;28 Suppl 4:71-7 [9761038.001]
  • [Cites] Hepatology. 1999 Jan;29(1):1-4 [9862841.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1760-74 [15578514.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S83-9 [15758665.001]
  • [Cites] J Infect Dis. 2005 Oct 15;192(8):1381-6 [16170755.001]
  • [Cites] JAMA. 1994 Dec 21;272(23 ):1845-50 [7990219.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Clin Liver Dis. 2006 May;10 (2):207-17, vii [16971258.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):802-11 [9466975.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1220-30 [16729305.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1331-6 [8229111.001]
  • [Cites] Hepatology. 2005 Dec;42(6):1364-72 [16317692.001]
  • [Cites] Chest. 2005 Jul;128(1):116-23 [16002924.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1170-9 [15486922.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Surg Res. 1998 Dec;80(2):252-8 [9878321.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):231-3 [16552791.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):e676-81 [16950959.001]
  • [Cites] Drug Metab Rev. 2004 May;36(2):301-12 [15237856.001]
  • [Cites] Chem Res Toxicol. 1998 Sep;11(9):969-88 [9760271.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):223-33 [16485898.001]
  • [Cites] Clin Pharmacol Ther. 2000 Apr;67(4):432-7 [10801254.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:23-30 [9138125.001]
  • [Cites] Dig Dis Sci. 1991 Sep;36(9):1223-8 [1716546.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):398-400 [7907127.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):493-503 [16859400.001]
  • [Cites] FASEB J. 2002 Aug;16(10 ):1227-36 [12153990.001]
  • [Cites] Gut. 1997 Oct;41(4):534-40 [9391255.001]
  • [Cites] Gastroenterology. 1990 Feb;98 (2):502-4 [2295408.001]
  • [Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):687-94 [16530510.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1603-12 [15185301.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:12-21 [9204405.001]
  • [Cites] Hepatology. 1992 Feb;15(2):244-51 [1735527.001]
  • [Cites] Science. 2001 Sep 7;293(5536):1829-32 [11546872.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):423-32 [11864614.001]
  • [Cites] Toxicol Pathol. 1996 Mar-Apr;24(2):181-9 [8992608.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1245-52 [10751350.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1587-91 [11075787.001]
  • [Cites] Immunol Rev. 2000 Apr;174:5-20 [10807503.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):422-30 [10648470.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6480-6 [10843705.001]
  • [Cites] Crit Rev Toxicol. 2005 Apr-May;35(4):325-61 [15989140.001]
  • [Cites] Hepatology. 2002 Aug;36(2):451-5 [12143055.001]
  • [Cites] Eur J Immunol. 2006 Apr;36(4):1028-38 [16552707.001]
  • [Cites] Drug Saf. 2001;24(7):483-90 [11444721.001]
  • [Cites] Annu Rev Immunol. 1994;12:991-1045 [8011301.001]
  • [Cites] Chem Res Toxicol. 1999 May;12(5):387-95 [10328748.001]
  • [Cites] Toxicol Sci. 2000 Apr;54(2):509-16 [10774834.001]
  • [Cites] Immunity. 2004 Oct;21(4):539-50 [15485631.001]
  • [Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:31-5 [9138126.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Apr 1;172(1):44-51 [11264022.001]
  • [Cites] Drug Saf. 2005;28(4):351-70 [15783243.001]
  • [Cites] Hepatology. 2000 Jan;31(1):201-6 [10613746.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Apr;61(2):135-43 [15726344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5498-503 [10792025.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):415-20 [16481451.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):435-55 [12732844.001]
  • [Cites] Hepatology. 2002 Apr;35(4):883-9 [11915035.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1849-54 [7768392.001]
  • [Cites] Ann Intern Med. 2002 Dec 17;137(12):947-54 [12484709.001]
  • [Cites] Hepatology. 2005 Aug;42(2):481-9 [16025496.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):512-21 [16083708.001]
  • [Cites] Cell Death Differ. 1999 Jun;6(6):516-24 [10381654.001]
  • [Cites] Hepatology. 2001 Jan;33(1):123-30 [11124828.001]
  • [Cites] Hepatology. 2006 Mar;43(3):618-31 [16496329.001]
  • [Cites] Hepatology. 2003 Apr;37(4):924-30 [12668988.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):962-71 [10500080.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):921-30 [11015434.001]
  • [Cites] Hepatology. 1995 Sep;22(3):767-73 [7657281.001]
  • [Cites] Neurology. 2001 May 22;56(10 ):1405-9 [11376200.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):286-301 [8419252.001]
  • [Cites] Hepatology. 2005 May;41(5):1179-97 [15841455.001]
  • [Cites] Toxicol Appl Pharmacol. 1995 Jul;133(1):43-52 [7597709.001]
  • [Cites] Dig Dis. 1994 Jul-Aug;12(4):191-8 [7850998.001]
  • [Cites] Hepatology. 2004 Jul;40(1):10-5 [15239079.001]
  • [Cites] J Hepatol. 1990 Sep;11(2):272-6 [2254635.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):716-9 [8780577.001]
  • [Cites] Clin Liver Dis. 2003 May;7(2):351-67 [12879988.001]
  • [Cites] Hepatology. 2001 Nov;34(5):964-71 [11679967.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):39-47 [10728793.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24453-6 [11356822.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:37-42 [9204408.001]
  • [Cites] Chest. 1991 Feb;99(2):465-71 [1824929.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):73-96, vi [11232192.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1541-51 [9834283.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1021-9 [9537442.001]
  • [Cites] Mol Pharmacol. 2001 Mar;59(3):627-35 [11179459.001]
  • [Cites] Clin Pharmacol Ther. 2001 Apr;69(4):223-31 [11309550.001]
  • [Cites] Immunol Rev. 2000 Apr;174:63-76 [10807507.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Ann Intern Med. 1984 Apr;100(4):495-9 [6230976.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6 [9620920.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):489-99 [15931258.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1323-30 [8229110.001]
  • [Cites] Am J Cardiol. 2000 Jun 22;85(12A):15E-9E [10858489.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • (PMID = 17408305.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  • [Number-of-references] 126
  •  go-up   go-down


59. Rozga J: Liver support technology--an update. Xenotransplantation; 2006 Sep;13(5):380-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver support technology--an update.
  • BACKGROUND: Currently, there is no direct treatment for hepatic failure, and patients must receive a transplant or endure prolonged hospitalization, with significant morbidity and mortality.
  • Because of the scarcity of donor organs, liver support strategies are being developed with the aim of either supporting patients with borderline functional liver cell mass until an appropriate organ becomes available for transplantation or until their livers recover from injury.
  • RESULTS: Currently, a number of blood purification systems and devices utilizing viable liver cells are in various stages of clinical development.
  • These systems are able to remove toxins of hepatic failure, and their utility is limited by their inability to provide missing liver-specific functions.
  • In contrast, hepatocyte-based devices are able to provide whole liver functions, including detoxification, biosynthesis, and biotransformation.
  • Molecular adsorbent recycling system (MARS) blood detoxification system has been tested in thousands of patients, but additional well-conducted controlled studies are warranted to better define the role of MARS in the treatment of patients with acute hepatic failure and acute exacerbation of chronic liver disease.
  • HepatAssist was tested in a phase II/III controlled clinical trial that demonstrated safety and proof of concept for use of biological liver support systems to improve patient survival in acute hepatic failure.
  • CONCLUSIONS: Developing an effective liver assist technology has proven difficult, because of the complexity of liver functions that must be replaced, as well as heterogeneity of the patient population.
  • Non-biological systems may have a role in the treatment of specific forms of liver failure where the primary goal is to provide blood detoxification/purification.
  • Biological systems appear to be useful in treating liver failure where the primary objective is to provide whole liver functions which are impaired or lost.
  • It is suggested that there will be a role for hybrid liver support systems that offer liver cell therapy and various forms of blood purification (sorption, hemofiltration and diafiltration) to treat patients with specific forms of liver failure at various stages of their illness.
  • [MeSH-major] Liver Failure, Acute / therapy. Liver, Artificial
  • [MeSH-minor] Animals. Hemodiafiltration / methods. Hepatocytes / metabolism. Humans. Liver Transplantation. Renal Dialysis / methods. Sorption Detoxification / methods. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925661.001).
  • [ISSN] 0908-665X
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 67
  •  go-up   go-down


60. Machado MA, Makdissi FF, Surjan RC, Kappaz GT, Yamaguchi N: Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis. Surg Endosc; 2010 Aug;24(8):2044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis.
  • BACKGROUND: Hepatectomy may prolong the survival of colorectal cancer patients with liver metastases.
  • Two-stage liver surgery is a valid option for the treatment of bilobar colorectal liver metastasis.
  • This video demonstrates technical aspects of a two-stage pure laparoscopic hepatectomy for bilateral liver metastasis.
  • To the authors' knowledge, this is the first description of a two-stage laparoscopic liver resection in the English literature.
  • METHODS: A 54-year-old man with right colon cancer and synchronous bilobar colorectal liver metastasis underwent laparoscopic right colon resection followed by oxaliplatin-based chemotherapy.
  • The patient then was referred for surgical treatment of liver metastasis.
  • Liver volumetry showed a small left liver remnant.
  • Surgical planning was for a totally laparoscopic two-stage liver resection.
  • The postoperative pathology showed high-grade liver steatosis.
  • After 4 weeks, the left liver had regenerated, and volumetry of left liver was 43%.
  • The line of liver transection was marked following the ischemic area.
  • Liver transection was accomplished with the Harmonic scalpel and an endoscopic stapling device.
  • The falciform ligament was fixed to maintain the left liver in its original anatomic position, avoiding hepatic vein kinking and outflow syndrome.
  • CONCLUSION: Two-stage liver resections can be performed safely using laparoscopy.
  • The intrahepatic Glissonian approach is a useful tool for pedicle control of the right liver, especially after previous dissection of the hilar plate.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Laparoscopy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Sep;246(3):385-92; discussion 392-4 [17717442.001]
  • [Cites] Br J Surg. 2005 May;92(5):592-5 [15779074.001]
  • [Cites] Ann Surg. 2008 Dec;248(6):994-1005 [19092344.001]
  • [Cites] Am J Surg. 2009 Jun;197(6):737-9 [18789420.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):784-8 [10383579.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):e38-42 [18614140.001]
  • [Cites] Am J Surg. 2009 Aug;198(2):173-7 [19268902.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2005 Jun;15(3):180-3 [15956908.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Jun;19(3):409-13 [19215213.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):918-20 [12912755.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):978-82; discussion 982 [18936377.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • (PMID = 20108150.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Reuben A: Alcohol and the liver. Curr Opin Gastroenterol; 2006 May;22(3):263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol and the liver.
  • PURPOSE OF REVIEW: To apprise the reader of advances in 2005 in the epidemiology, pathogenesis, prognosis and treatment of alcoholic liver disease.
  • Alcohol use has declined in developed countries, but the opposite is true elsewhere; alcoholic liver disease is a considerable burden worldwide.
  • RECENT FINDINGS: Genetic mechanisms for alcoholic liver disease are being discovered in addition to aggravating cofactors, such as hepatitis C, obesity and iron overload, and ameliorating ones, like coffee and tea drinking.
  • The involvement of the innate immune system and the mechanisms of apoptosis in alcoholic liver disease are better appreciated, especially the emerging role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • Steroid use and nutrition for alcoholic hepatitis are being refined, and the validity of the model for end-stage liver disease (MELD) score in predicting the outcome of alcoholic liver disease is upheld.
  • Recidivism after liver transplantation for alcoholic liver disease adversely impacts long-term survival.
  • SUMMARY: Inroads are being made into the genetics of alcoholic liver disease and new phenomena are being uncovered in its pathogenesis, but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wanting.
  • [MeSH-major] Liver Diseases, Alcoholic / etiology. Liver Diseases, Alcoholic / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550041.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


62. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg; 2007 Nov;42(11):1797-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal and neonatal hepatic tumors.
  • BACKGROUND/PURPOSE: Although hepatic tumors are uncommon in the perinatal period they are associated with significant morbidity and mortality in affected patients.
  • The purpose of this review is to focus on the fetus and neonate in an attempt to determine the various ways liver tumors differ clinically and pathologically from those found in the older child and adult and to show that certain types of tumors have a better prognosis than others.
  • METHODS: The author conducted a retrospective review of perinatal hepatic tumors reported in the literature and of patients treated and followed up at Children's Hospital San Diego and Children's Hospital Los Angeles.
  • Discussion of the differential diagnosis and pathologic findings of hepatic tumors in the fetus and neonate are described elsewhere and will not be discussed here in detail (Perspect Pediatr Pathol 1978;4:217; Weinberg AG, Finegold MJ.
  • Primary hepatic tumors in childhood.
  • Pathology of neoplasia in children and adolescents.
  • Liver tumors. In: Isaacs H Jr, editor.
  • Tumors of the fetus and newborn.
  • Liver tumors. In: Isaacs H Jr, editor.
  • Tumors of the fetus and infant: an atlas.
  • RESULTS: One hundred ninety-four fetuses and neonates presented with hepatic tumors diagnosed prenatally (n = 56) and in the neonatal period (n = 138).
  • The study consisted of 3 main tumors: hemangioma (117 cases, 60.3%), mesenchymal hamartoma (45 cases, 23.2%), and hepatoblastoma (32 cases, 16.5%).
  • The 56 fetuses and 138 neonates with hepatic tumors (hemangioma, mesenchymal hamartoma, and hepatoblastoma) had survival rates of 75%, 64%, and 25%, respectively.
  • The overall survival of the entire group consisting of 194 tumors was 125 or 64%.
  • CONCLUSIONS: The study shows that clinical findings in fetuses and neonates with hepatic tumors are less well defined than in older children.
  • Some hepatic tumors have a better prognosis than others.
  • Neonates with focal (solitary) hepatic hemangiomas have the best outcome and fetuses with hepatoblastoma the worst.
  • Mesenchymal hamartoma is a benign lesion best treated by surgical resection, which usually results in cure.
  • However, there are fatal complications associated with this tumor, ie, fetal hydrops, respiratory distress, and circulatory problems owing to a large space occupying abdominal lesion and sometimes stillbirth, all contributing to the death rate.
  • Pre- or postoperative chemotherapy is reserved for those patients with unresectable tumors or metastatic disease.
  • Patients die from the mass effect caused by the tumor, which lead to abdominal distension, vascular compromise, anemia, hydrops, respiratory distress, and stillbirth.
  • Because of the danger of labor-induced rupture of the tumor and potentially fatal intraabdominal hemorrhage, cesarean delivery is recommended when a hepatic tumor is found on prenatal ultrasound.
  • [MeSH-major] Hamartoma / congenital. Hemangioma / congenital. Hepatoblastoma / congenital. Liver Neoplasms / congenital. Liver Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022426.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


63. Bouchnak M, Souissi K, Ouragini H, Abbes Z, Douiri H, Maghrebi H: [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome]. Tunis Med; 2005 Aug;83(8):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome].
  • [Transliterated title] Intérêt de la corticothérapie en post partum dans le HELLP (hemolysis elevated liver enzymes low platelets count) syndrome.
  • Our purpose was to assess the effects of corticotherapy prescribed after delivery on the kinetic of biological parameters of HELLP syndrome (hemolysis elevated liver enzymes low platelets count).
  • The kinetic of the hepatic cytolysis marker was not modified by corticotherapy.

  • Genetic Alliance. consumer health - HELLP syndrome.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238275.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Placebos; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


64. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD: Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res; 2008 Jan 15;14(2):419-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: More than 200 precursor and mature miRNAs were profiled by real-time PCR in 43 and 28 pairs of HCC and adjacent benign liver, respectively, and in normal liver specimens.
  • RESULTS: Several miRNAs including miR-199a, miR-21, and miR-301 were differentially expressed in the tumor compared with adjacent benign liver.
  • A large number of mature and precursor miRNAs were up-regulated in the adjacent benign liver specimens that were both cirrhotic and hepatitis-positive compared with the uninfected, noncirrhotic specimens (P < 0.01).
  • Comparing the miRNA expression in the HCC tumors with patient's survival time revealed two groups of patients; those with predominantly lower miRNA expression and poor survival and those with predominantly higher miRNA expression and good survival (P < 0.05).
  • CONCLUSION: We show that a global increase in the transcription of miRNA genes occurs in cirrhotic and hepatitis-positive livers and that miRNA expression may prognosticate disease outcome in HCC.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(1):161-73 [17223503.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 7:S16 [18047715.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10843-8 [17108120.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1203-17 [16990141.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3801-9 [16799621.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):15-21 [16706806.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):103-6 [16175574.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 1999 Dec;13(4):545-55 [10654919.001]
  • [Cites] Dev Cell. 2003 Aug;5(2):351-8 [12919684.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] J Hepatol. 2003;39 Suppl 1:S59-63 [14708679.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):215-9 [15050913.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Trends Biochem Sci. 2004 Sep;29(9):462-8 [15337119.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52361-5 [15504739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • (PMID = 18223217.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100882; United States / NCI NIH HHS / CA / CA107435-02; United States / NCI NIH HHS / CA / R01 CA100882; United States / NCI NIH HHS / CA / R21 CA107435-02; United States / NCI NIH HHS / CA / CA107435; United States / NCI NIH HHS / CA / R56 CA100882; United States / NCI NIH HHS / CA / R21 CA107435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS82897; NLM/ PMC2755230
  •  go-up   go-down


65. Wasmuth HE, Trautwein C: [Liver fibrosis : clinics, diagnostics and management]. Internist (Berl); 2010 Jan;51(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver fibrosis : clinics, diagnostics and management].
  • Liver fibrosis results from chronic liver damage and is characterized by scarring of the liver parenchyma.
  • Liver fibrosis can occur in all chronic liver diseases and shows progression towards liver cirrhosis in 20-40% of cases.
  • The clinical presentation of liver fibrosis is usually unspecific.
  • Therefore, most patients with liver fibrosis are identified by elevated liver enzymes during other medical examinations.
  • The gold standard for quantification of liver fibrosis is percutaneous liver biopsy, but non-invasive markers (e. g. serum markers, transient elastography) have recently been evaluated to identify individuals with significant fibrosis.
  • In case of fibrosis detection, medical therapies aim at stabilizing liver scarring or even at inducing the regression of fibrosis.
  • Primarily this is achieved by etiology specific therapies of chronic liver diseases (e. g. antiviral therapy, immunosuppressive therapy etc.).
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Liver Cirrhosis / diagnosis. Liver Cirrhosis / drug therapy

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Sep;135(3):821-9 [18593587.001]
  • [Cites] Hepatology. 2007 Mar;45(3):569-78 [17326152.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):309-19, 319.e1-3 [19344719.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):1022 [12297856.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] World J Gastroenterol. 2009 Mar 28;15(12):1409-14 [19322911.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1661-3 [17969048.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] BMC Gastroenterol. 2007 Oct 15;7:40 [17937811.001]
  • [Cites] Hepatology. 2008 Aug;48(2):418-31 [18563841.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2297-307 [17135584.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1670-81 [18471546.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Hepatology. 2008 Mar;47(3):789-98 [18175357.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] Hepatology. 2007 Sep;46(3):912-21 [17705266.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] Hepatology. 2006 Aug;44(2):472-7 [16871557.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):257-65 [12586290.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23 ):2429-41 [19052125.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1704-13 [15578508.001]
  • (PMID = 19921111.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


66. Nunes ML, Rault A, Teynie J, Valli N, Guyot M, Gaye D, Belleannee G, Tabarin A: 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg; 2010 Jul;34(7):1506-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
  • BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been proposed for the evaluation of adrenal tumors.
  • However, only scarce data are available to evaluate its usefulness for the identification of primary adrenal carcinomas in patients with no previous history of cancer and equivocal tumors on computed tomography (CT) scan.
  • Twenty-three consecutive patients without previous history of cancer investigated for adrenal tumors without features of benign adrenocortical adenoma on CT scan but no obvious ACC underwent 18F-FDG PET.
  • The ratio of maxSUV adrenal tumor on maxSUV liver (adrenal/liver maxSUV ratio) during 18F-FDG PET was compared to Weiss pathological criteria.
  • RESULTS: Seventeen patients had an adrenal adenoma, 2 had small size adrenal carcinomas (<5 cm), 1 had an angiosarcoma, and 3 had noncortical benign lesions.
  • An adrenal/liver maxSUV ratio above 1.6 provided 100% sensitivity, 90% specificity, and 100% negative predictive value for the diagnosis of malignant tumor.
  • CONCLUSIONS: Because of its excellent negative predictive value, 18F-FDG-PET may be of help in avoiding unnecessary surgery in patients with non-secreting equivocal tumors at CT scanning and low 18F-FGD uptake.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnostic imaging. Adrenal Gland Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):871-7 [15572420.001]
  • [Cites] Radiology. 2005 Feb;234(2):479-85 [15671003.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2018-25 [18566816.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] J Nucl Med. 2001 Jun;42(6):884-92 [11390552.001]
  • [Cites] Radiology. 2006 Mar;238(3):970-7 [16505394.001]
  • [Cites] Int J Clin Pract. 2007 May;61(5):802-9 [17343665.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1713-22 [19190108.001]
  • (PMID = 20396886.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


67. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg; 2009 Nov;250(5):738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.
  • BACKGROUND/PURPOSE: Liver transplantation (LT) is the best theoretical treatment of hepatocellular carcinoma (HCC) fulfilling the Milan criteria (TNM stages 1-2).
  • However, LT is limited by organ availability and tumor progression on the waiting list.
  • Liver resection (LR) may represent an alternative in these patients.
  • PATIENTS: From 1990 to 2007, 274 patients underwent liver resection for HCC.
  • Ten were TNM stage 1 and 57 stage 2 and all had chronic liver disease.
  • After a mean follow-up of 4.8 years, 36 patients (54%) developed intrahepatic tumor recurrence.
  • Survival was not influenced by TNM stage 1 or 2, AFP level, tumor differentiation, or the presence microscopic vascular invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatitis / complications. Hepatitis C / complications. Humans. Liver Cirrhosis, Alcoholic / complications. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


68. Schober AK, Hahn EG, Harsch IA: [A 67-year-old patient with recurrent hypoglycemia]. Internist (Berl); 2008 Apr;49(4):485-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging techniques revealed a tumor of the pancreas involving the spleen with metastases of the liver, expressing somatostatin receptors.
  • In case of diagnosed insulinoma, underlying MEN (multiple endocrine neoplasia) should be considered.
  • Excision of the tumor is recommended in patients with benign solitary insulinomas.
  • Thus, in contrast to other extended tumors, surgery is reasonable in malignant insulinoma even in case of metastatic disease.
  • [MeSH-major] Hypoglycemia / etiology. Insulinoma / secondary. Liver Neoplasms / secondary. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Blood Glucose / metabolism. C-Peptide / blood. Chromogranin A / blood. Diagnosis, Differential. Disease Progression. Female. Humans. Insulin / blood. Magnetic Resonance Imaging. Palliative Care. Recurrence. Ultrasonography

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Physiol Scand Suppl. 1968;314:1-60 [4973243.001]
  • [Cites] Endocr J. 2007 Feb;54(1):95-101 [17124362.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):2839-42 [16684819.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):519-23 [1310159.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):311-24 [15763703.001]
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1144-52 [7700289.001]
  • [Cites] J Nucl Med. 2004 Jul;45(7):1161-7 [15235062.001]
  • [Cites] Horm Res. 2006;65(3):120-5 [16479142.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92 (4):1237-44 [17227804.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Nov;65(5):566-78 [17054456.001]
  • [Cites] Diabetologia. 1977 Apr;13(2):117-24 [404204.001]
  • [Cites] Diabetes. 2006 Jan;55(1):13-8 [16380471.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):560-6 [15809476.001]
  • [Cites] World J Surg. 2005 Jun;29(6):789-93 [15880279.001]
  • (PMID = 18324381.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Chromogranin A; 0 / Insulin
  •  go-up   go-down


69. Montalvo-Jave EE, Villegas-Alvarez F, Montalvo-Arenas CE, Peña-Sánchez J, Gutiérrez-Vega R, Piña E: Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review. Rev Gastroenterol Mex; 2009 Oct-Dec;74(4):341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review.
  • Liver transplantation constitutes a constant challenge in finding viable options to maintain or recover an adequate function when faced with end-stage liver failure.
  • Critical review of the literature was conducted in specific topics on liver transplantation and development in Mexico.
  • We focused our review on medical and surgical topics such as liver procurement from a related living donor, liver transplantation options for patients with liver cancer, especially hepatocellular carcinoma and cholangiocarcinoma, as well as on cellular and molecular biology aspects, such as xenotransplantation and hepatocyte transplantation.
  • [MeSH-major] Cell Transplantation. Liver Neoplasms / surgery. Liver Transplantation. Tissue and Organ Procurement


70. Bueno J, Escartín A, Balsells J, Margarit C: Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children. Transplant Proc; 2007 Sep;39(7):2278-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children.
  • Hepatic hemodynamic changes during liver transplantation (OLT) in children have not yet been studied.
  • We measured intraoperative portal vein flow (PVF) and hepatic arterial flow (HAF) (mL/min) in 53 children and 58 grafts during OLT.
  • In the native liver, PVF and HAF are similar; after transplantation they return to the physiological situation.
  • Among the 8 (14%) portal vein thromboses, PVF was lower in both the native liver and the graft than in the no thrombosis group (P < .05).
  • [MeSH-major] Liver Circulation. Liver Transplantation. Monitoring, Intraoperative
  • [MeSH-minor] Blood Flow Velocity. Child. Hepatic Artery / physiology. Humans. Portal Vein / physiology. Thrombosis / diagnosis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889162.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Song CH, Chen LM, Zhang LX: [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun;21(2):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease].
  • OBJECTIVE: To analyze the influence of the model for end-stage liver disease (MELD) results in 409 cases with liver cirrhosis and severe hepatitis and compare with Child-Pugh scoring system.
  • METHODS: The data of 409 patients with liver cirrhosis and severe hepatitis were collected and analyzed by using the Child-Pugh and MELD scoring systems, and Chiss statistical software was applied.
  • CONCLUSION: The changes in total serum bilirubin and creatinine can influence the result significantly, not the INR, and a better way to predict the prognosis of severe liver disease may be application of MELD combined with clinical experience.
  • [MeSH-major] Hepatitis / diagnosis. Liver Cirrhosis / diagnosis. Liver Failure / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653326.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


72. Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French SW, Morgan TR: Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol; 2008 Sep;20(9):843-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
  • OBJECTIVE: To determine whether expression of transcription factors and lipogenic enzymes is altered in liver and adipose tissue of mice with obesity, insulin resistance, and nonalcoholic fatty liver disease.
  • MEASUREMENTS: Liver injury was evaluated by histology and serum aminotransferase levels.
  • RESULTS: HF mice weighed more, had insulin resistance, hepatic steatosis, and focal pericellular hepatic fibrosis.
  • Hepatic expression of sterol regulatory element-binding protein-1c, carbohydrate response element-binding protein, liver X receptor-alpha, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) decreased during fasting in SF and HF mice; however, FAS expression and protein content were higher in the liver of fasted HF mice than of fasted SF mice.
  • In adipose tissue, expression of sterol response element-binding protein-1c, carbohydrate response element-binding protein, liver X receptor-alpha, peroxisome proliferator-activated receptor-gamma, ACC, and FAS decreased with fasting in mice fed SF, but not in HF mice.
  • During fasting, hepatic FAS expression and protein content are increased in HF mice.
  • De-novo lipogenesis may persist in liver and adipose tissue during fasting in obesity/nonalcoholic fatty liver disease.
  • [MeSH-major] Fatty Liver / genetics. Gene Expression Regulation. Lipogenesis / genetics. Liver / metabolism. Obesity / genetics

  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794597.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Grant] United States / PHS HHS / / P50-011999-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Transcription Factors; 0 / Triglycerides; EC 2.3.1.85 / Fatty Acid Synthases; EC 6.4.1.2 / Acetyl-CoA Carboxylase
  •  go-up   go-down


73. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J: Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant; 2005 Feb;5(2):399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?
  • Concern exists that partial liver transplants (either a living donor [LD] or deceased donor [DD] in hepatitis C virus (HCV)-positive recipients may be associated with an increased risk for recurrence.
  • From 1999 to 2003, at our institution, 51 HCV-positive recipients underwent liver transplants: 32 whole-liver (WL) transplants, 12 LD transplants and 7 DD split transplants.
  • Donor characteristics differed in that WL donors were older, and LD livers had lower ischemic times.
  • With a mean follow-up of 28.3 months, 46 (90%) recipients are alive: three died from HCV recurrent liver disease and two from tumor recurrence.
  • Liver regeneration does not seem to affect hepatitis C recurrence as much, perhaps, as factors such as DD status, donor age and cold ischemic time.
  • [MeSH-major] Hepatitis C / surgery. Liver Regeneration. Liver Transplantation. Living Donors


74. Norén B, Lundberg P, Ressner M, Wirell S, Almer S, Smedby O: Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease. Eur Radiol; 2005 Jan;15(1):148-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.
  • Phosphorus-31 NMR spectroscopy using slice selection (DRESS) was used to investigate the absolute concentrations of metabolites in the human liver.
  • Nine patients with histopathologically proven diffuse liver disease and 12 healthy individuals were examined in a 1.5-T MR scanner (GE Signa LX Echospeed plus).
  • (1) determination of optimal depth for the in vivo measurements, (2) mapping the detection coil characteristics, (3) calculation of selected slice and liver volume ratios using simple segmentation procedures and (4) spectral analysis in the time domain.
  • Absolute concentration measurements of phosphorus metabolites in the liver are feasible using a slice selective sequence, and the technique demonstrates significant differences between patients and healthy subjects.
  • [MeSH-major] Liver Diseases / metabolism. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Hydrogen-Ion Concentration. Liver Function Tests. Male. Middle Aged. Phosphorus Isotopes. Sensitivity and Specificity. Signal Processing, Computer-Assisted. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 1989 Nov;12(2):282-9 [2559292.001]
  • [Cites] Prog Biophys Mol Biol. 1996;65(1-2):45-81 [9029941.001]
  • [Cites] J Biol Chem. 1987 Jan 5;262(1):35-7 [3793728.001]
  • [Cites] Liver. 1997 Aug;17(4):198-209 [9298490.001]
  • [Cites] Anal Biochem. 1990 Dec;191(2):193-222 [2085167.001]
  • [Cites] Hepatology. 1995 Feb;21(2):417-27 [7843715.001]
  • [Cites] MAGMA. 2002 Mar;14(1):30-8 [11796250.001]
  • [Cites] Magn Reson Imaging. 1992;10(6):949-56 [1461092.001]
  • [Cites] NMR Biomed. 1996 Jun;9(4):141-55 [9015801.001]
  • [Cites] NMR Biomed. 1996 May;9(3):93-104 [8892395.001]
  • [Cites] Dig Dis Sci. 1994 Jan;39(1):33-8 [8281864.001]
  • [Cites] MAGMA. 2001 Aug;13(1):40-6 [11410395.001]
  • [Cites] Clin Sci (Lond). 1990 Jan;78(1):33-8 [2153493.001]
  • [Cites] Magn Reson Med. 1994 Oct;32(4):453-8 [7997109.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):953-8 [2069850.001]
  • [Cites] JAMA. 1999 Nov 3;282(17):1659-64 [10553793.001]
  • [Cites] NMR Biomed. 1999 Dec;12(8):535-44 [10668046.001]
  • [Cites] Hepatology. 2003 Apr;37(4):788-94 [12668971.001]
  • [Cites] Magn Reson Imaging. 2000 Feb;18(2):181-7 [10722978.001]
  • [Cites] Magn Reson Med. 1989 Oct;12(1):145-50 [2558272.001]
  • [Cites] NMR Biomed. 1992 May-Jun;5(3):114-20 [1322688.001]
  • [Cites] Acta Radiol. 1998 May;39(3):309-14 [9571950.001]
  • [Cites] NMR Biomed. 1993 Mar-Apr;6(2):168-72 [8499248.001]
  • [Cites] Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7 [8241291.001]
  • [Cites] Metabolism. 1996 Sep;45(9):1059-61 [8781290.001]
  • [Cites] Gut. 1996 Jul;39(1):141-6 [8881826.001]
  • [Cites] Biochemistry. 1968 Nov;7(11):4030-4 [4972613.001]
  • [Cites] NMR Biomed. 1993 May-Jun;6(3):215-24 [8347456.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):776-88 [7875480.001]
  • [Cites] Scand J Clin Lab Invest. 1975 May;35(3):245-51 [1153922.001]
  • [Cites] Biochim Biophys Acta. 1995 Oct 17;1272(2):113-8 [7548234.001]
  • [Cites] Biochim Biophys Acta. 1978 Dec 4;514(1):1-8 [718902.001]
  • [Cites] Gut. 1990 Apr;31(4):463-7 [2338275.001]
  • [Cites] Magn Reson Med. 1988 Jan;6(1):92-8 [3352510.001]
  • [Cites] Radiology. 1989 Nov;173(2):393-400 [2798871.001]
  • [Cites] Am J Physiol. 1994 Feb;266(2 Pt 2):R638-45 [8141425.001]
  • [Cites] Magn Reson Imaging. 1998;16(2):205-11 [9508277.001]
  • [Cites] J Magn Reson Imaging. 1992 Mar-Apr;2(2):183-90 [1562769.001]
  • [Cites] Hepatology. 1995 Feb;21(2):443-9 [7843719.001]
  • [Cites] Magn Reson Med. 1994 Oct;32(4):447-52 [7997108.001]
  • [Cites] Gut. 2002 Jan;50(1):118-22 [11772978.001]
  • (PMID = 15351899.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphorus Isotopes
  •  go-up   go-down


75. Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I: Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem; 2009 Apr;42(6):455-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
  • OBJECTIVES: Hepatitis C virus (HCV) is a major aetiological agent of chronic hepatitis and it leads to the development of liver cirrhosis and hepatocellular carcinoma (HCC).
  • The significances of p53 protein and anti-p53 antibodies levels in HCV genotype IV infected patients with different liver pathology were evaluated.
  • DESIGN AND METHODS: Immunostaining and western blot based on monospecific anti-p53 antibody were used for the identification of p53 protein in liver tissues and serum samples.
  • RESULTS: Mild and diffuse p53 cytoplasmic immunostaining was found in liver tissues of patients with liver fibrosis [F1-F3] and liver cirrhosis [F4] in comparison with strong and diffuse p53 cytoplasmic immunostaining in patients with HCC.
  • The target p53 protein was identified in sera of patients with liver fibrosis, liver cirrhosis and HCC at 53-kDa.
  • The detection rate of serum p53 protein increases significantly (p<0.05) with the progression of the liver pathology.
  • However, a significant difference (p<0.05) was only shown between serum p53 protein level of HCC patients and those of other liver pathology.
  • In contrast, anti-p53 IgG antibodies positive rates showed only a significant decrease (p<0.05) in HCC in comparison with liver cirrhosis.
  • CONCLUSIONS: The serum and cytoplasmic p53 protein expressions were more pronounced in patients with HCC more than liver cirrhosis, and in liver cirrhosis more than liver fibrosis.
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Hepatitis C, Chronic / blood. Liver / metabolism. Liver Cirrhosis / blood. Liver Neoplasms / blood. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19063876.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunoglobulin G; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Stutchfield BM, Rashid S, Forbes SJ, Wigmore SJ: Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection. Stem Cells Dev; 2010 Feb;19(2):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection.
  • Liver resection has been associated with significant morbidity and mortality due to hepatic dysfunction or hepatic failure in the postoperative period.
  • Autologous bone marrow stem cell (BMSC) therapy may offer the potential to enhance hepatic regeneration in this setting, perhaps increasing the safety of the procedure.
  • Preclinical models and initial translational studies have suggested that autologous BMSC administration can facilitate hepatic regeneration following both acute and chronic liver disease.
  • While translational studies have begun in chronic hepatic disease, translation to hepatic surgical indications has been limited.
  • This review explores the practical barriers currently restricting the delivery of autologous stem cell therapies to enhance hepatic regeneration following liver resection including selection of cell type, cell isolation, therapy delivery, trial design, and assessment of efficacy.
  • [MeSH-major] Bone Marrow Transplantation / methods. Liver Diseases / physiopathology. Liver Diseases / surgery. Liver Regeneration

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954303.001).
  • [ISSN] 1557-8534
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


77. Barshes NR, Lee TC, Udell IW, O'mahoney CA, Karpen SJ, Carter BA, Goss JA: The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients. Liver Transpl; 2006 Mar;12(3):475-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients.
  • The pediatric end-stage liver disease (PELD) model accurately estimates 90-day waitlist mortality for pediatric liver transplant candidates, but it has been unclear if PELD can identify patients who will derive survival benefit from undergoing liver transplantation (LT), if it correlates with posttransplant survival, or if it can identify patients for whom LT would be futile.
  • Complete data were available for 1,247 patients: 53% were listed as Status 1 at the time of orthotopic liver transplantation (OLT), while the remaining 47% had PELD scores.
  • In conclusion, pediatric patients with a PELD score of 17+ derive survival benefit early after LT, and increasing PELD scores are associated with increasing transplant benefit after liver transplantation.
  • [MeSH-major] Algorithms. Cause of Death. Liver Failure / mortality. Liver Transplantation / mortality. Postoperative Complications / mortality. Tissue and Organ Procurement

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 AASLD
  • (PMID = 16498644.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J: Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther; 2008 Sep;19(9):915-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter.
  • The hepatocarcinoma-intestine-pancreas (HIP) gene, also called pancreatitis-associated protein-1 (PAP1) or Reg IIIalpha, is activated in most human hepatocellular carcinomas (HCCs) but not in normal liver, which suggests that HIP regulatory sequence could be used as efficient liver tumor-specific promoters to express a therapeutic polynucleotide in liver cancer.
  • For this purpose, we constructed a recombinant rat HIP-NIS adenoviral vector (AdrHIP-NIS), and evaluated its performance as a mediator of selective radioiodide uptake in tumor hepatocytes.
  • Western blot, immunofluorescence, and iodide uptake assays were performed in AdrHIP-NIS-infected primary hepatocytes and transformed hepatic and nonhepatic cells.
  • Nuclear imaging, tissue counting and immunohistochemistry were performed in normal and HCC-bearing Wistar rats infected with AdrHIP-NIS intratumorally or via the hepatic artery.
  • In AdrHIP-NIS-infected transformed hepatic cells, functional NIS was strongly expressed, as in cells infected with a cytomegalovirus-NIS vector.
  • In rats bearing multinodular HCC, AdrHIP-NIS triggered functional NIS expression that was preferential in tumor hepatocytes.
  • This study has identified the rHIP regulatory sequence as a potent liver tumor-specific promoter for the transfer of therapeutic genes, and AdrHIP-NIS-mediated (131)I therapy as a valuable option for the treatment of multinodular HCC.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Lectins, C-Type / genetics. Liver Neoplasms, Experimental / radiotherapy. Liver Neoplasms, Experimental / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Base Sequence. Cell Line. Cell Line, Tumor. DNA, Recombinant / genetics. Dogs. Female. Gene Expression. Gene Transfer Techniques. Genetic Vectors. Humans. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / therapeutic use. Male. Promoter Regions, Genetic. Rats. Rats, Wistar. Symporters / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759560.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Recombinant; 0 / Iodine Radioisotopes; 0 / Lectins, C-Type; 0 / Symporters; 0 / pancreatitis-associated protein; 0 / sodium-iodide symporter
  •  go-up   go-down


79. Shin N, Hasegawa K, Ikeda M, Ishizawa T, Kokudo N, Sugawara Y, Makuuchi M: Adult intussusception induced by the stump of the jejunal loop after liver transplantation. Hepatogastroenterology; 2008 May-Jun;55(84):898-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult intussusception induced by the stump of the jejunal loop after liver transplantation.
  • Intussusception occurs rarely in adults compared with children, and in the case of adults, some organic disease, such as a benign or malignant tumor, can be found at the leading edge of the intussusception in about 90% of adult cases.
  • [MeSH-major] Anastomosis, Roux-en-Y. Choledochostomy. Intussusception / surgery. Jejunal Diseases / surgery. Liver Transplantation. Postoperative Complications / surgery
  • [MeSH-minor] Adult. Cholangitis, Sclerosing / surgery. Diagnosis, Differential. Hepatitis C, Chronic / surgery. Humans. Jejunostomy. Liver Cirrhosis / surgery. Male. Reoperation


80. Lordan JT, Worthington TR, Quiney N, Fawcett W, Karanjia ND: Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients. HPB (Oxford); 2009 Jun;11(4):321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients.
  • BACKGROUND: Liver resection is an accepted treatment modality for malignant disease of the liver.
  • However, because of its potential morbidity and mortality, the practice of liver resection in benign disease is more controversial.
  • This study was designed to assess the early outcomes of 79 consecutive liver resections for benign disease over a 12-year period and compare these with early outcomes of 390 consecutive liver resections for metastatic colorectal cancer (MCRC) during the same period.
  • METHODS: Consecutive liver resections were carried out in a single hepatopancreatobiliary (HPB) centre between 1996 and 2008.
  • RESULTS: There was no difference in median age between the benign group vs. the MCRC group (P = 0.181).
  • However, there was a significant trend towards a lower ASA grade in the benign group (P < 0.001).
  • Morbidity rates were 8.9% in the benign group and 20.5% in the MCRC group (P = 0.002).
  • The rate of serious complications was 1.3% in the benign group compared with 4.4% in the MCRC group (P = 0.041).
  • There were no postoperative deaths in the benign group and eight (2%) in the MCRC group (P = 0.004).
  • CONCLUSIONS: Liver resection for benign liver tumours can be undertaken with a mortality rate approaching zero and minimal morbidity in specialist HPB units.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):302-6 [18328668.001]
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Am J Surg. 2007 Jan;193(1):5-9 [17188079.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1192-201 [16983740.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):86-96 [15864693.001]
  • [Cites] BMC Surg. 2005;5:5 [15774004.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):13-8 [7740799.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):190-5 [2840865.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • (PMID = 19718359.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2727085
  • [Keywords] NOTNLM ; benign liver disease / liver resection
  •  go-up   go-down


81. Ritchie AH, Williscroft DM: Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature. Can J Rural Med; 2006;11(4):283-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature.
  • Liver injury secondary to blunt abdominal trauma is a well-defined entity in emergency medicine.
  • A challenge exists in the diagnosis of liver trauma in the stable, wellappearing patient with a history of blunt abdominal trauma.
  • In centres lacking advanced diagnostic modalities an elevation in hepatic transaminases may provide guidance for the rural emergency physician in seeking further imaging and/or surgical consultation.
  • There appears to be a direct relationship between blunt liver trauma and elevation in liver transaminases.
  • [MeSH-major] Abdominal Injuries / blood. Liver / injuries. Transaminases / blood. Wounds, Nonpenetrating / diagnosis
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054829.001).
  • [ISSN] 1203-7796
  • [Journal-full-title] Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la médecine rurale : le journal officiel de la Société de médecine rurale du Canada
  • [ISO-abbreviation] Can J Rural Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 2.6.1.- / Transaminases
  • [Number-of-references] 27
  •  go-up   go-down


82. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, Galle PR, Otto G: Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl; 2010 Mar;16(3):314-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience.
  • Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present.
  • Seven patients received a pacemaker prior to LT, and because of impairment of mechanical cardiac function, 4 combined heart-liver transplants were performed, 1 simultaneously and 3 sequentially.
  • Cardiac symptoms occurred predominantly in patients with non-Val30Met mutations and prompted combined heart-liver transplantation in 4 patients.
  • Combined heart-liver transplantation should be considered in patients with restrictive cardiomyopathy.
  • [MeSH-major] Amyloid Neuropathies, Familial / surgery. Heart Transplantation. Liver Transplantation


83. Lau WY, Lai EC: Hepatic resection for colorectal liver metastases. Singapore Med J; 2007 Jul;48(7):635-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for colorectal liver metastases.
  • INTRODUCTION: Nearly 50 percent of patients who have colorectal carcinoma will develop liver metastases, which is frequently the cause of death.
  • Liver resection is the only curative treatment for patients with colorectal metastases confined to the liver.
  • However, liver resection can be performed in only ten percent of patients.
  • A strategy to improve resectability and outcome of patients with colorectal liver metastases is needed.
  • METHODS: The progress and outcome of patients, who had colorectal liver metastases and underwent liver resection in a tertiary surgical centre between January 1998 and December 2002, were retrospectively studied.
  • RESULTS: During the five-year study period, 42 patients with colorectal liver metastasis underwent hepatic resection.
  • 36 patients received primary liver resection.
  • Six patients with initially unresectable disease received salvage surgery after tumour downstaging with systemic chemotherapy.
  • Five of the 42 patients needed repeat liver resection for recurrent colorectal liver metastases.
  • The five-year survival rate with salvage surgery after tumour downstaging was 34 percent, and the corresponding figure, after repeat liver resection, for recurrent liver metastases was 27 percent.
  • CONCLUSION: Hepatic resection for colorectal metastases confined to the liver resulted in reasonably good long-term survival, with acceptably low operative mortality and morbidity.
  • Our results were compatible with the international standard of liver resection for colorectal liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609825.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


84. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol; 2008 Jun;19(6):1146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases.
  • BACKGROUND: The benefit of surgical resection of liver metastases from gastric cancer has not been well established.
  • The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer.
  • METHODS: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery.
  • RESULTS: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years.
  • The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival.
  • CONCLUSIONS: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved.
  • Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304963.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Steurer W: [Liver transplantation]. Praxis (Bern 1994); 2006 Sep 20;95(38):1465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation].
  • Liver transplantation has developed as standard therapy for end-stage liver disease and fulminant hepatic failure with excellent results.
  • The application of new techniques including split liver and living donor liver transplantation (LDLT) has only marginally increased the total number of liver transplants.
  • [MeSH-major] Liver Diseases / surgery. Liver Failure / surgery. Liver Neoplasms / surgery. Liver Transplantation


86. Iimuro Y, Brenner DA: Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res; 2008 Feb;25(2):249-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase gene delivery for liver fibrosis.
  • The resolution of advanced liver fibrosis has been recently recognized to be possible, if the causative stimuli are successfully removed.
  • However, whether complete resolution from cirrhosis, the end stage of liver fibrosis, can be achieved is still questionable.
  • Delivery of interstitial collagenases, such as matrix metalloproteinase (MMP)-1, in the liver could be an attractive strategy to treat advanced hepatic fibrosis from the view point that the imbalance between too few interstitial collagenases and too many of their inhibitors is the main obstacle to the resolution from fibrosis.
  • Remodeling of hepatic extracellular matrix by delivered interstitial collagenases also facilitates the disappearance of activated hepatic stellate cells, the main matrix-producing cells in the liver, and promotes the proliferation of hepatocytes.
  • This review will focus on the impact of the gene delivery of MMPs for the treatment of advanced liver fibrosis while discussing other current therapeutic strategies for liver fibrosis, and on the need for the development of a safe and effective delivery system of MMPs.
  • [MeSH-major] Genetic Therapy. Liver Cirrhosis / therapy. Matrix Metalloproteinases / genetics

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Nov;40(5):1106-15 [15389776.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1151-9 [15389867.001]
  • [Cites] Am J Med. 1970 Nov;49:707-21 [4924592.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1709-13 [3287167.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):175-84 [2293576.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):1786-93 [2592560.001]
  • [Cites] Cell Mol Biol. 1990;36(2):131-53 [2165861.001]
  • [Cites] Hepatology. 1991 Feb;13(2):282-8 [1995439.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):282-7 [1634616.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1014-21 [1398481.001]
  • [Cites] J Hepatol. 1992 Jul;15(3):336-44 [1447500.001]
  • [Cites] Semin Cell Biol. 1993 Jun;4(3):189-201 [7688595.001]
  • [Cites] Clin Chim Acta. 1993 Sep 17;218(1):47-58 [8299219.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):528-37 [8129038.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5858-69 [8065319.001]
  • [Cites] Virchows Arch. 1994;424(1):25-31 [7981900.001]
  • [Cites] J Biochem. 1995 Sep;118(3):643-9 [8690730.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):821-31 [8608892.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1847-53 [8964410.001]
  • [Cites] J Hepatol. 1996 Aug;25(2):200-5 [8878782.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):238-45 [8907579.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G116-23 [9038884.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1297-306 [9098016.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Apr;21(2):375-9 [9113278.001]
  • [Cites] Gut. 1997 Jan;40(1):133-8 [9155591.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):554-61 [9314134.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1069-73 [9322499.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1265-72 [9358752.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1530-7 [9397994.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):139-52 [9428228.001]
  • [Cites] Hepatology. 1998 Mar;27(3):720-6 [9500700.001]
  • [Cites] J Hepatol. 1998 Apr;28(4):615-21 [9566830.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):538-49 [9691091.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1525-31 [9828216.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1895-902 [9846979.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2573-6 [9881484.001]
  • [Cites] J Hepatol. 2006 Sep;45(3):429-38 [16846660.001]
  • [Cites] Hepatology. 2007 Jan;45(1):213-22 [17187438.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11069-76 [11796725.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1525-8 [11984538.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):739-45 [12174389.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):850-60 [12297832.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1647-52 [12457277.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):445-58 [12557150.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):504-20 [12557155.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8083-90 [12502711.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):468-75 [12663239.001]
  • [Cites] Liver Transpl. 2003 Apr;9(4):331-8 [12682882.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):378-86 [9922319.001]
  • [Cites] Nat Med. 1999 Feb;5(2):226-30 [9930873.001]
  • [Cites] Hepatology. 1999 Oct;30(4):944-50 [10498646.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1304-11 [15565662.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):56-65 [15630444.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):108-20 [15633128.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13 [15618280.001]
  • [Cites] Annu Rev Biochem. 2005;74:711-38 [15952901.001]
  • [Cites] FASEB J. 2006 Mar;20(3):444-54 [16507762.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1807-21 [16697743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12719-24 [10535989.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1053-61 [10604579.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1120-30 [10604588.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2247-50 [10644669.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):32-8 [10728792.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1149-56 [10833490.001]
  • [Cites] J Hepatol. 2000 May;32(5):762-70 [10845663.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G245-9 [10915630.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1599-607 [11079009.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):545-51 [11124055.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] Curr Top Pathol. 1999;93:205-18 [10339913.001]
  • [Cites] Gut. 2001 Apr;48(4):548-57 [11247901.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1784-800 [11375959.001]
  • [Cites] J Hepatol. 2001 May;34(5):764-7 [11434626.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):148-55 [11438504.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28274-80 [11346654.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):685-98 [11522753.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):745-50 [11584371.001]
  • [Cites] Semin Liver Dis. 2001 Aug;21(3):437-51 [11586471.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):392-8 [11592601.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40591-8 [11509553.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):474-81 [11682031.001]
  • [Cites] Clin Liver Dis. 2001 Nov;5(4):1073-90 [11685796.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD002148 [11687017.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d496-503 [11815289.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):178-91 [12851882.001]
  • [Cites] Br J Pharmacol. 2003 Jul;139(6):1085-94 [12871826.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Sep;15(9):951-7 [12923366.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1849-58 [14578185.001]
  • [Cites] Tissue Eng. 2003 Dec;9(6):1289-99 [14674437.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):955-63 [15057733.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1122-33; discussion 949 [15057751.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Hepatology. 2004 May;39(5):1390-7 [15122768.001]
  • [Cites] BMC Gastroenterol. 2003 Oct 18;3:29 [14565855.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):766-77 [15077122.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1795-808 [15188175.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):235-41 [15288472.001]
  • [Cites] Hepatology. 1999 Mar;29(3):858-67 [10051490.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2345-9 [10051644.001]
  • (PMID = 17577645.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 105
  • [Other-IDs] NLM/ PMC2245995
  •  go-up   go-down


87. Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M: Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr; 2010;2:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.
  • BACKGROUND: Despite ongoing findings on the relationship between elevated levels of alanine and aspartate aminotransferases (ALT and AST) and metabolic syndrome (MetS), this association in diabetic patients without a known cause for liver enzymes elevation other than diabetes, per se, remains unclear.
  • In this study, we aimed to assess the relationship between circulating liver enzymes and MetS in a relatively large sample of patients with diabetes.
  • Patients with ultrasonographic signs of fatty liver disease were not included.
  • CONCLUSION: In diabetic patients without ultrasonographic evidence of fatty liver, elevated aminotransferases are independently associated with MetS.
  • Despite negative ultrasound results in diabetic patients with MetS, the serum level of liver aminotransferases may be elevated and should be more thoroughly monitored.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047423.001).
  • [ISSN] 1758-5996
  • [Journal-full-title] Diabetology & metabolic syndrome
  • [ISO-abbreviation] Diabetol Metab Syndr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987914
  •  go-up   go-down


88. Hanouneh IA, Zein NN: Metabolic syndrome and liver transplantation. Minerva Gastroenterol Dietol; 2010 Sep;56(3):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome and liver transplantation.
  • Non-alcoholic fatty liver disease (NAFLD), an important consequence of the global epidemic of obesity, is a common indication of orthotopic liver transplantation in the western world.
  • Currently, NAFLD is the fourth most common indication of liver transplantation in the United Stated with prediction for increase demand of liver transplantation for NAFLD cirrhosis in the next two decades to exceed that of liver transplantation for chronic hepatitis C virus infection.
  • Given the advances in the efficacy and tolerability of immunosuppressive agents which have reduced the incidence of chronic rejection, long-term survival rates after liver transplantation have remarkably improved.
  • Today, long-term graft loss and death after liver transplantation are commonly related to age-related complications, such as cardiovascular disease.
  • Features of metabolic syndrome including obesity, hypertension, hyperglycemia and dyslipidemia are very prevalent and almost universal after liver transplantation.
  • These metabolic derangements are intricately associated with cardiovascular events and have emerged as the leading cause of morbidity and mortality after liver transplantation.
  • In addition, the international epidemic of obesity has negatively impacted the liver transplant candidacy.
  • Because obesity is associated with poor postoperative outcome, many transplant centers decline liver transplantation for morbidly obese individuals above certain level of body mass index.
  • [MeSH-major] Liver Transplantation. Metabolic Syndrome X / complications. Postoperative Complications / etiology


89. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL: Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation; 2006 Nov 27;82(10):1298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database.
  • BACKGROUND: There may be an allograft-enhancing effect by the liver on the renal allograft in the setting of simultaneous combined liver-kidney transplantation (CLKT) from the same donor.
  • This study was performed to investigate whether an existing liver allograft could protect a kidney allograft from immunologic injury due to histoincompatibility in liver transplant recipients who received sequential kidney transplantation (KALT).
  • CONCLUSION: Liver allograft provided renal graft immunoprotection if both organs are transplanted simultaneously (immunogenetic identity), but not for kidneys transplanted subsequently.
  • [MeSH-major] Graft Rejection / epidemiology. Graft Survival / physiology. Kidney Transplantation / physiology. Liver Transplantation / physiology. Tissue and Organ Procurement / statistics & numerical data


90. Boehnert MU, Hilbig H, Armbruster FP: Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver. Ann N Y Acad Sci; 2005 May;1041:434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver.
  • The study investigates the protective effect of relaxin on liver tissue against cell damage during organ preservation and reperfusion.
  • Liver transplantation was simulated in a model of isolated perfused rat liver.
  • To quantify cell damage, we examined the perfusate for malonyldialdehyde (MDA) and myeloperoxidase activity (MPO), and liver tissue underwent immunohistochemical study.
  • [MeSH-major] Liver / drug effects. Liver Transplantation / methods. Models, Animal. Organ Preservation / methods. Organ Preservation Solutions / chemistry. Relaxin / pharmacology. Reperfusion Injury / prevention & control

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956742.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organ Preservation Solutions; 0 / Solutions; 4Y8F71G49Q / Malondialdehyde; 9002-69-1 / Relaxin
  •  go-up   go-down


91. von Oppen N, Schurich A, Hegenbarth S, Stabenow D, Tolba R, Weiskirchen R, Geerts A, Kolanus W, Knolle P, Diehl L: Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology; 2009 May;49(5):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization.
  • Peripheral CD8 T-cell tolerance can be generated outside lymphatic tissue in the liver, but the course of events leading to tolerogenic interaction of hepatic cell populations with circulating T-cells remain largely undefined.
  • Here we demonstrate that preferential uptake of systemically circulating antigen by murine liver sinusoidal endothelial cells (LSECs), and not by other antigen-presenting cells in the liver or spleen, leads to cross-presentation on major histocompatibility complex (MHC) I molecules, which causes rapid antigen-specific naïve CD8 T-cell retention in the liver but not in other organs.
  • [MeSH-major] Antigen Presentation. CD8-Positive T-Lymphocytes / immunology. Cross-Priming. Endothelial Cells / immunology. Liver / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205034.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 9006-59-1 / Ovalbumin
  •  go-up   go-down


92. Obach RS, Dobo KL: Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessment. Environ Mol Mutagen; 2008 Oct;49(8):631-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessment.
  • Because it is well known that metabolites of chemicals and drugs are frequently the ultimate species responsible for genotoxicity and carcinogenicity, in vitro testing to identify the human genotoxicity hazard potential of new chemicals and drugs routinely utilizes liver S-9 fraction from rats treated with Aroclor 1254 as a system that can generate metabolites.
  • To address this, 16 common drugs have been examined for profiles of metabolites in Aroclor-induced rat liver S-9 and pooled human liver S-9.
  • These findings suggest that when conducting in vitro genotoxicity testing using the Aroclor-induced rat liver S-9 system, knowledge of the metabolite profile in the system is important, and a comparison to the profile generated in human liver S-9 could be of value when interpreting the genotoxicity results.
  • [MeSH-major] Aroclors / toxicity. Liver / drug effects. Mutagens / toxicity. Subcellular Fractions / drug effects


93. Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E: Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep; 2006 Mar;15(3):551-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
  • Hepatoblastoma (HBL), a major childhood malignant neoplasm, represents the most frequent malignant liver tumor in childhood.
  • We investigated the genetic alterations of the CTNNB1 coding beta-catenin protein and expression of several genes downstream of Wnt signals in 4 benign and 17 malignant pediatric liver tumors (PLTs) consisting of 15 HBL, 1 hepatocellular carcinoma, and 1 hepatic immature sarcoma.
  • The immunohistochemical studies in 17 malignant PLTs demonstrated the nuclear/cytoplasmic accumulation of beta-catenin to be positive in all tumor specimens except for one hepatic sarcoma.
  • A histological examination revealed all HBL cases involving tumors without detectable CTNNB1 gene alterations to show high expression of beta-catenin, thus indicating the accumulation of beta-catenin to be a common event in malignant PLTs, including HBL and hepatocellular carcinoma.
  • On the other hand, the expression of cyclin D1, a gene downstream of beta-catenin, might play a role in tumor progression.
  • [MeSH-major] Liver Neoplasms / diagnosis. Mutation. beta Catenin / genetics
  • [MeSH-minor] Cadherins / analysis. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Child. Child, Preschool. Cyclin D1 / analysis. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Hepatoblastoma / diagnosis. Hepatoblastoma / genetics. Hepatoblastoma / metabolism. Humans. Immunohistochemistry. Infant. Male. Prognosis


94. Rubio-Tapia A, Murray JA: The liver in celiac disease. Hepatology; 2007 Nov;46(5):1650-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The liver in celiac disease.
  • Celiac disease is a common (1% prevalence) chronic immune-mediated disorder of the small intestine induced by dietary wheat, barley, and rye.
  • Several hepatic disorders have been described in association with celiac disease.
  • Isolated hypertransaminasemia with nonspecific histologic changes in a liver biopsy is the commonest hepatic presentation of celiac disease.
  • A gluten-free diet normalizes liver enzymes and histologic changes in most patients.
  • Moreover, celiac disease can coexist with autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.
  • Celiac disease has increasingly been reported with a variety of other liver diseases.
  • Thus, the hepatologist needs to consider celiac disease in the differential of abnormal liver blood tests and to be aware of the clinical implications of this frequent disease in patients with liver disorders.
  • The possible mechanisms of liver injury and those common factors that explain the association of celiac disease with liver disorders are discussed.
  • The aims of this article are (1) to review the spectrum and pathogenesis of liver injury related to celiac disease and (2) to provide direction to those caring for patients with chronic liver diseases regarding the detection and effective treatment of celiac disease.
  • [MeSH-major] Celiac Disease / complications. Liver Diseases / etiology
  • [MeSH-minor] Antibodies / blood. Cholangitis, Sclerosing / epidemiology. Cholangitis, Sclerosing / etiology. Cholangitis, Sclerosing / therapy. Gliadin / immunology. Hemochromatosis / complications. Humans. Liver Transplantation. Pancreatic Diseases / complications. Prevalence. Transglutaminases / immunology


95. Berends MA, van Oijen MG, Snoek J, van de Kerkhof PC, Drenth JP, Han van Krieken J, de Jong EM: Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol; 2007 Dec;143(12):1515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens.
  • OBJECTIVE: To determine the interobserver reliability of the Roenigk score as a classification system of liver damage and its possible consequences for clinical practice.
  • Patients One hundred sixty liver biopsy specimens from patients with psoriasis receiving methotrexate treatment were rereviewed and analyzed blindly by an experienced pathologist with an interest in liver pathologic conditions.
  • Conclusion The Roenigk classification in the assessment of liver fibrosis is a reliable scoring system.
  • [MeSH-major] Dermatologic Agents / adverse effects. Drug-Induced Liver Injury. Liver Diseases / pathology. Methotrexate / adverse effects. Psoriasis / drug therapy. Severity of Illness Index
  • [MeSH-minor] Biopsy. Female. Humans. Liver / pathology. Male. Reproducibility of Results. Retrospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18087000.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


96. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased PADI4 expression in blood and tissues of patients with malignant tumors.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • Levels of PADI4 and citrullinated antithrombin (cAT) were investigated in the blood of patients with various tumors by ELISA (n = 1121).
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • CONCLUSION: Our results suggest that PADI4 expression is increased in the blood and tissues of many malignant tumors, a finding useful for further understanding of tumorigenesis.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


97. Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D: Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther; 2009 Jun;16(6):746-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
  • Using this animal model, we compared two plasmid gene administration techniques: muscle electrotransfer and liver-directed transfer using hydrodynamic injection.
  • The liver seemed to be more appropriate than the muscle as a target organ to enable enzyme secretion into the systemic circulation.
  • A beneficial effect on the MPS VII pathology was also observed, as liver-directed gene transfer led to the correction of secondary enzymatic elevations and to the reduction of GAGs storage in peripheral tissues and brain, as well as to histological correction in many tissues.
  • [MeSH-major] Gene Transfer Techniques. Glycoside Hydrolases / genetics. Glycoside Hydrolases / metabolism. Liver / metabolism. Mucopolysaccharidosis VII / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357715.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Glycosaminoglycans; 0 / RNA, Messenger; EC 3.2.1.- / Glycoside Hydrolases
  •  go-up   go-down


98. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF: Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int; 2008 Dec;28(10):1408-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis.
  • Abstract Aim: To correlate liver stiffness with demographical factors and routine liver biochemistry and to assess the predictive value of these as potential markers of fibrosis.
  • According to a previous validated study for CHB, liver stiffness of >8.1 and >10.3 kPa were used as cut-off values for defining severe fibrosis and cirrhosis respectively.
  • RESULTS: Liver stiffness correlated positively with bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), globulin, alpha-fetoprotein (AFP) and HBV DNA levels and negatively with albumin and platelet levels (P<0.05 for all correlations).
  • From 13 parameters (age, sex, platelet, AST, ALT, GGT, AFP, albumin, globulin, bilirubin, ALP, HBV DNA and hepatitis B e-antigen), four best parameters (AST, platelet, GGT and AFP) were used to derive a liver stiffness model.
  • CONCLUSION: Routine liver biochemistry correlated well with liver stiffness in Asian CHB patients.
  • A model using simple serum markers can predict liver stiffness, and further studies are required to validate the usefulness of these simple tests as non-invasive markers of fibrosis in CHB.
  • [MeSH-major] Hepatitis B, Chronic / pathology. Liver / metabolism. Liver Cirrhosis / diagnosis. Models, Biological

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482268.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Globulins; 0 / alpha-Fetoproteins; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


99. Yamskova VP, Borisenko AV, Krasnov MS, Il'ina AP, Rybakova EY, Malcev DI, Yamskov IA: Effect of bioregulators isolated from the liver, blood serum, and bile of mammals on the state of newt liver tissue in organotypic culture. Bull Exp Biol Med; 2010 Dec;150(1):140-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of bioregulators isolated from the liver, blood serum, and bile of mammals on the state of newt liver tissue in organotypic culture.
  • We developed models of in vitro organotypic culturing of newt liver tissue with and without adhesion to the substrate.
  • The effects of bioregulators isolated from mammalian liver, blood serum, and bile were studied on the developed models and their specificity was demonstrated.
  • The state of the liver was evaluated by the area of clusters of pigmented cells and by the number of mitoses in the connective tissue cells of the cortical layer.
  • These bioregulators exhibited their biological effects only under conditions of roller organotypic culturing of newt liver tissue.
  • [MeSH-major] Bile / chemistry. Growth Substances / isolation & purification. Growth Substances / pharmacology. Liver / chemistry. Liver / cytology. Organ Culture Techniques / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21161073.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  •  go-up   go-down


100. Droy L, Sagan C, Paineau J, Gournay J, Mosnier JF: [Cholangiocarcinomas developing on multiple bile duct hamartomas syndrome]. Ann Pathol; 2009 Feb;29(1):24-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In each case, the clinical and radiological investigations showed a liver tumor with no other concomitant disease.
  • Tumors were resected, and microscopic examination revealed in one case a hilar cholangiocarcinoma, in the other case a peripheric cholangiocarcinoma, both being well-differentiated.
  • It revealed also numerous bile duct hamartomas scattered throughout the liver.
  • In one case, some bile duct hamartomas showed a gradual morphologic transition from benign to dysplastic and neoplastic epithelium.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hamartoma / pathology
  • [MeSH-minor] Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Cell Division. Disease Progression. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233090.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down